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Micronization techniques based on supercritical fluids (SCFs) are promising for the 
production of particles with controlled size and distribution. The interest of the 
pharmaceutical field in the development of SCF techniques is increasing due to the need for 
clean processes, reduced consumption of energy, and to their several possible applications. 
The food field is still far from the application of SCF micronization techniques, but there is 
increasing interest mainly for the processing of products with high added value. 
The aim of this study is to use SCF micronization techniques for the production of particles 
of pharmaceuticals and food ingredients with controlled particle size and morphology, and 
to look at their production on semi-industrial scale. The results obtained are also used to 
understand the processes from the perspective of broader application within the 
pharmaceutical and food industries. Certain pharmaceuticals, a biopolymer and a food 
ingredient have been tested using supercritical antisolvent micronization (SAS) or 
supercritical assisted atomization (SAA) techniques. 
The reproducibility of the SAS technique has been studied using physically different 
apparatuses and on both laboratory and semi-industrial scale. Moreover, a comparison 
between semi-continuous and batch mode has been performed. The behaviour of the 
system during the SAS process has been observed using a windowed precipitation vessel. 
The micronized powders have been characterized by particle size and distribution, 
morphology and crystallinity. Several analyses have been performed to verify if the SCF 
process modified the structure of the compound or caused degradation or contamination of 
the product. The different powder morphologies obtained have been linked to the position 
of the process operating point with respect to the vapour-liquid equilibrium (VLE) of the 
systems studied, that is, mainly to the position of the mixture critical point (MCP) of the 
mixture. 
Spherical micro, submicro- and nanoparticles, expanded microparticles (balloons) and 
crystals were obtained by SAS. The obtained particles were amorphous or with different 
degrees of crystallinity and, in some cases, had different pseudo-polymorphic or 
polymorphic forms. A compound that could not be processed using SAS was micronized by 
SAA, and amorphous particles were obtained, stable in vials at room temperature. 
The SCF micronization techniques studied proved to be effective and versatile for the 
production of particles for several uses. Furthermore, the findings of this study and the 
acquired knowledge of the proposed processes can allow a more conscious application of 
SCF techniques to obtain products with the desired characteristics and enable the use of 
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The production of particles with controlled size and morphology has conventionally been a 
fundamental target for pharmaceutical industries. Microparticles with particle size in the 
range 1-5 μm to be used e.g. for inhalation delivery or aerosol devices and nanoparticles 
with size <0.5 μm to be used in liquid formulation are produced systematically [1]. More 
attention is now given also to the chemical and physical solid-state properties of the 
obtained particles, mainly their crystal structure, habit and the degree of crystallinity. These 
characteristics can have a relevant influence on the formulation, manufacturing of solid 
dosage form, storage stability, and properties of the final product [2,3]. 
The interest of food industries in nano and micro technology has not yet reached the same 
level, because of the limited applications of small particles as food products. However, with 
the continuous development of the functional foods and nutraceuticals market, more 
attention is currently given to products that can also deliver nutrients and bioactive 
compounds and, as a consequence, to the size and morphology of the particles [4,5]. 
Moreover, in some applications the use of particles or crystals of controlled particle size and 
morphology can facilitate the process of obtaining the final product. One example is the use 
of additives in foods or beverages to give a smooth structure to the matrix. 
The use of SCF-based micronization techniques becomes of more interest due to the general 
tendency in every field to use clean processes to preserve the future of the planet. SCF 
techniques are a good solution to the environmental problems because of the limited use of, 
and sometimes the complete absence of, organic solvents in the process, the low energy 
required for carrying out the process and the absence of post-processing steps. 
The interest in using SCFs in the pharmaceutical field is related to the difficulty of 
controlling physico-chemical properties of the particles produced using conventional 
manufacturing processes and to the importance of obtaining a product with the 
characteristics required for the final formulation into aerosols, tablets, injectable 
suspensions or capsules. Moreover, the international regulations for the use of solvents in 
pharmaceutical industries [6] require controlled use of organic solvents and the radical 
reduction of conventional solvents used in pharmaceutical processes. 
The regulations on hygiene and good manufacturing practices [7] are also strict in the 
production of food-related compounds, because the human health is involved in the widest 
possible sense. Moreover, the processing of some compounds with a SCF may be 
particularly advantageous, like in the case of compounds that can degradate in presence of 





Carbon dioxide (CO2) still remains the most used SCF, either in the micronization or 
extraction processes, mainly because it is non-toxic, non-flammable and cheap. It can also 
be re-circulated during the process or reused many times. It behaves as a lipophilic solvent 
and produces a non-oxidizing process environment. 
The most studied SCF micronization technique is the supercritical antisolvent (SAS) 
process, in which supercritical-carbon dioxide (SC-CO2) has the same role as the antisolvent 
in classical liquid antisolvent crystallization. Despite the many examples of applications 
that can be found in the literature [9-14], when a compound to be micronized is selected, it 
is difficult to find the relations between the operating parameters and the results. Although 
the process is highly complex, several published papers attempted to explain separately the 
role of atomization [15], mass transfer [16-18], nucleation and growth [19,20] and a 
significant progress has been made in attempting to isolate the effects of each of these 
factors using carefully designed experiments. 
The choice of a satisfactory scale-up procedure also requires a deep understanding of the 
controlling steps of the process. Some authors proposed the scale-up of the SAS process to 
pilot scale. However, up to now only few examples of successful application of SAS at pilot 
scale to the production of micrometric particles can be found in the literature [21,22]. 
One of the most recent SCF micronization processes uses SC-CO2 as co-solute, Supercritical 
Assisted Atomization (SAA), which interacts in the system as a pneumatic agent and 
improves the micronization induced by the spray in a way similar to a pneumatic gas in a 
spray drying process. The SAA technique [23] can be considered as the complement of the 
antisolvent technique, and may be used in all the cases where SAS is unsuccessful. The 
technique is still relatively new; therefore, not enough results are available to build up a 
model and the micronization mechanism has to be studied further. 
The interest in the application of SCF-based micronization techniques to pharmaceutical 
and food-related compounds and the perception of the mechanisms involved in these 
processes are of interest to chemists, pharmacists and chemical engineers. The chemical 
engineer is fascinated by the powerful potentiality of a process as versatile and complex as 
micronization involving high-pressure equilibria systems. The pharmaceutical researcher 
can make use of the possibility of controlling the physico-chemical properties of the final 
compound to develop the desired formulation. The chemist finds challenges in the study of 
the structural modifications that may occur in an environment far from the usual 
micronization or reaction media. Finally, the food chemist can be surprised in discovering 





2  REVIEW OF LITERATURE 
Supercritical fluids (SCFs) are gases at temperature and pressure conditions above their 
critical point. The possibility of modulating viscosity and density and, consequently, the 
solvent power allows to consider them as liquid-like or gas-like, depending on the 
conditions and the applications. It has been known for more than a century that SCFs can 
dissolve non-volatile compounds [24,25]; indeed, they have been used for three decades in 
chromatography analysis [26]. The first industrial applications of SCFs have taken 
advantage of these properties as solvent for the extraction (SFE: Supercritical Fluid 
Extraction) of compounds of special value from solid and liquid matrices and for 
fractionating them [27-31]. 
In the last 20 years, a most challenging application has been to use SCFs to produce 
micronized powders of controlled particle size and distribution [10,12,14]. The different 
SCF-based micronization techniques were developed for several categories of compounds: 
pharmaceuticals [25,32-34], polymers and biopolymers [13,35], proteins [36], inorganic 
materials (explosives, colouring matters, catalysts, superconductors) [10] and 
nanocomposites [37]. The application to pharmaceutical compounds has been developed 
far, mainly with the view of exploring processes that could give new characteristics to the 
compound itself either in the formulation or the delivery systems. Up to now, very few 
applications to food ingredients can be found, and those that can generally concern food 
products with a high added value. 
In this literature review, the results of the most diffused SCF-based micronization 
techniques are presented. Among the information that can be found in literature, the 
criterion applied has been to consider mainly peer reviewed publications and not to refer to 
materials coming from conference proceedings, because sometimes they report incomplete 
studies or just the starting points of ongoing research. SCF micronization techniques are 
briefly described, and a rich collection of results, selected for their accuracy and 
thoroughness of information, is presented. 
2.1 SCF micronization techniques 
SCF-based micronization techniques can be classified according to the role played by the 
SCF in the process. Indeed, SCFs have been proposed as solvents, solutes, anti-solvents and 





Table 1. Classification of SCF-based micronization techniques according to the role of SCF in 
the process 
CO2 role application process acronym characteristics 
Rapid Expansion of Supercritical 
Solutions RESS 
supercritical solution sprayed 
into atmospheric pressure 
Rapid Expansion of a Supercritical 
solution into a Liquid SOLVent RESOLV 
supercritical solution sprayed 
into a liquid 
solvent compounds soluble in SC-CO2 
Rapid Expansion of a Supercritical 
Solution-Solid Cosolvent RESS-SC solid co-solvent added to SC-CO2 
Gas AntiSolvent GAS batch operation 
Supercritical AntiSolvent SAS semi-continuous operation 
Supercritical AntiSolvent with 
Enhanced Mass transfer SAS-EM 
semi-continuous operation, 
vibration added to precipitation 
vessel 
Solution Enhanced Dispersion by 
Supercritical fluids SEDS 
semi-continuous operation, SC-
CO2 and solvent mixed in a tube-
in-tube injector 
Aerosol Solvent Extraction System ASES semi-continuous operation  
Precipitation by Compressed 
Antisolvent PCA 
semi-continuous operation, CO2 





CO2, soluble in a 
solvent that has a 
good affinity with 
SC-CO2 
Supercritical Fluid-drying SCF-drying solvent used water and CO2 modified with polar solvent 
Particles from Gas Saturated Solution PGSS semi-continuous operation 
solute 
compounds in 
which SC-CO2 is 
soluble Supercritical Melting Micronization ScMM semi-continuous operation 
Carbon dioxide Assisted 
Nebulization-Bubble Drying CAN-BD 
low volume mixer for SCCO2-
solution 
Depressurization of an Expanded 
Liquid Organic Solution DELOS 
compressed CO2 used to 
homogenous cooling of the 






CO2, soluble in a 
solvent in which 
SC-CO2 is soluble 
Supercritical Assisted Atomization SAA enhanced solubilization mixing SCCO2-solution 
2.1.1 SCF as solvent 
The Rapid Expansion of Supercritical Solutions (RESS) consists of the saturation of the 
supercritical fluid with a solid substrate. The depressurization of the resulting solution 
through a heated nozzle into a low-pressure vessel produces a rapid nucleation of the 
substrate in the form of very small particles that are collected from the gaseous stream. The 
morphology of the resulting solid material, crystalline or amorphous, depends on the 
chemical structure of the material and on the RESS parameters (temperature, pressure drop, 
impact distance of the jet against a surface, nozzle geometry, etc.) [10,38]. The very fast 
release of the solute in the gaseous medium should assure the production of very small 





The authors who first proposed RESS [39,40] patented the process with respect to the 
possibility of producing nanoparticles, microparticles and films [41-43]. However, papers 
on this topic in the scientific literature confirmed this possibility only several years later 
[10,44]. The most important condition to be respected in the RESS technique is that the 
compound to be micronized has to be soluble in the SCF. This is also the most restrictive 
parameter for the application of this technique. Unfortunately, many pharmaceutical 
compounds of interest have high molecular weights and polar bonds and show a very low 
or negligible solubility in SC-CO2, which is the most widely used SCF. 
An interesting variation of the RESS process is the RESOLV (Rapid Expansion of a 
Supercritical solution into a Liquid SOLVent), which consists of spraying the supercritical 
solution into a liquid, which often contains a stabilizer [45]. When operating in this manner, 
it should be possible to quench particle growth in the precipitator, thus improving the RESS 
process performance. Moreover, by interaction among the nucleating solid particles and the 
compounds contained in the liquid phase, a chemical reaction step can also be added. Kropf 
et al. [46] patented a RESS-like process in which the supercritical solution is expanded into a 
gas or liquid and nanoparticles that can range between 10 and 300 nm are produced. 
Subsequently, Foerster et al. [47] and Kropf et al. [48] patented the generation of nanometric 
particles of chitosan and sterols using this process. 
The potential features of RESS are very interesting from the theoretical point of view, but 
the results have not been particularly good in several cases. The main problem is in 
controlling the particle size of the precipitates. During the expansion, the particles coalesce 
in the supersonic free jet generated in the precipitation vessel and, therefore, needle-like 
particles have been obtained in many cases (Table 2). Sometimes the formation of oriented 
needles can be explained by the presence of electrostatic charges on the surface of the 
particles induced by the fast relative motion between the particles and the gas contained in 
the expansion vessel [49]. RESOLV configuration has been demonstrated to be more 
effective in producing nanoparticles, since the liquid that receives the expanding jet can 
suppress the particle growth. The addition of a stabilizing agent in the liquid also protects 
particles from agglomeration. RESOLV has the additional problem of recovering the 
particles from the liquid solution used to improve the process performance: in this 
configuration, the process is no more solventless. When the solvent used is water, the 
process is useful for the production of suspensions for pharmaceutical formulations [50]. 
In Table 2 several examples of pharmaceutical compounds micronized using RESS and SC-






Thakur and Gupta [51-53] proposed a variation of the RESS process, which is named  
RESS-SC (Rapid Expansion of a Supercritical Solution-Solid Cosolvent), to overcome this 
limitation. They added to the SC-CO2 a solid co-solvent, which can enhance the solubility of 
many compounds in SCFs, provides a barrier for coagulation in the expansion vessel and is 
easily removed by sublimation. The compound that respects all these characteristics is 
menthol (m.p. 32-34°C). The compound to be micronized is solubilized in the SCCO2-
menthol mixture and the process is then carried out as a traditional RESS. Using this 
process, the authors micronized griseofulvin, a highly crystalline drug with low solubility 
in SC-CO2, and obtained separated particles [51] as opposed to the coalescing irregular 
particles obtained by RESS [54]. 
Chiou et al. [55] have proposed another modification of the RESS process. It consists of 
flowing the SC-CO2 with the dissolved solute (meloxicam) in a filter positioned before the 
expansion vessel. The process is called PF-RESS (Pre-Filtering Rapid Expansion of 
Supercritical Solutions), but there is no relevant difference from the classical RESS. 
The RESS process finds many applications to food ingredients because of the affinity of 
many natural compounds with SC-CO2 (Table 2), and both spherical particles [54] and 
crystal shape particles [56,57] have been produced. Low-molecular-weight polymers such 
as paraffin wax materials have reasonable high solubility in SC-CO2, while many polymers 
and bio-polymers have very limited or nearly zero solubility in SC-CO2; therefore, they can 
not be easily processed by this technique. 
Since the early publications on the RESS technique, a modelling approach to particles 
formation has been widely investigated [58-60] and several models for particle formation 
have been developed [60-62]. Recently, Weber and Thies [63] presented a simplified and 
generalized model accounting for the micronization and growth of particles in the RESS 
process, which could confirm theoretical findings from early works and reach satisfying 
agreement between modelling and experiments. 
Table 2. Pharmaceutical compounds, bio-polymers and food ingredients micronized by SCF-
based techniques. SCF used as solvent. 
material process/notes results/observations particle size ref 
pharmaceuticals 
2-aminobenzoic acid RESS-SC irregular particles, menthol used as solid co-solvent mean 80 nm [52] 
acetylsalicilic acid RESS needle-like crystals D90=7-19 μm [64] 
artemisinin RESS crystalline particles mean 0.5-10.6 μm [65] 
aspirin RESS isomeric particles with long needle-like crystals 2-5 μm [66] 





material process/notes results/observations particle size ref 
pharmaceuticals 
benzoic acid RESS isomeric particles long needle-like crystals 
2-8 μm 
0.2-0.3 μm [66] 
benzoic acid RESS   0.8-1.2 μm [59] 
benzoic acid RESS aggregate particles 0.2-1.4 μm [60] 
carbamazepine RESS needle-like, prismatic, elongated prismatic crystals, Form II, Form III 
0.5-2.5 μm, 
mean <3 μm [68] 
cholesterol RESS   <35 μm [59] 
cholesterol RESS aggregate particles 100-400 μm [60] 
cholesterol RESS needle-like crystals rod-like crystals 
1-6 μm, 1-13 μm; 
mean 13 μm [69] 
cholesterol RESS   0.3-0.5 μm [70,71] 
cyclosporine A RESS amorphous spherical particles mean 4.5 μm [72] 
fluorinated 




tetraphenylporphyrin RESOLV well separated spherical particles 23-33 nm [74] 
griseofulvin RESS aggregate spherical particles mean 200±50 nm [54] 
griseofulvin RESS-SC irregular particles, menthol as solid co-solvent 50-250 nm [51] 
ibuprofen RESS capillary nozzle mean 2 μm [75] 
ibuprofen RESS irregular particles, decreased degree of crystallinity 2.85-7.48 μm [76] 
ibuprofen RESOLV well separated irregular spherical particles mean 40 nm [50] 
ibuprofen RESS irregular agglomerated crystalline particles primary particles 100 nm [77] 
loperamide RESS spherical particles aggregated or not, depending from the nozzle and the use of co-solvent 
0.3-0.5 μm, 
1-7 μm [78] 
medroxyprogesterone 
acetate RESS irregular particles mean 4.5 μm [79] 
meloxicam PF-RESS irregular shape particles 0.5-2 μm [55] 
naphtalene RESS   1.5-3 μm [59] 
naproxen RESOLV well separated irregular spherical particles mean 64 nm [50] 
phenantrene RESS irregular crystals 1-5 μm [66] 
phenantrene RESSOLV crystals, dispersion in water 0.5-1 μm [78] 
phenylbutazone RESS crystals, metastable form β, no polymorphic modifications 1.5-4.3 μm [80] 
phenytoin RESS-SC irregular particles, menthol as solid co-solvent average 200 nm [53] 
progesterone RESS irregular particles mean 4.5 μm [79] 
salicylic acid RESS needle-like crystals 2-5 μm [81] 





squared crystals L/d=15.73 μm/ 4.06 μm [82] 
taxol RESS elongated crystals 0.3-1.7 μm [82] 





material process/notes results/observations particle size ref 
bio-polymers 
HYAFF 11 RESS regular microspheres <10 μm [83] 
PDLLA RESS irregular sized particles 10-20 μm [84] 
PGA RESS rectangles, oval particles needles 
10-20 μm 
length 40 μm [84] 
PLLA RESS, CO2, CO2+acetone 
microparticles and microspheres 4-25 μm [84] 










PLLA RESS, CO2+THF 
nanoparticles dispersed in micro and 
agglomerated particles 30-100 nm [86] 
PMMA RESS, CO2+EtOH 








separated spherical particles 1.5-2 μm [87] 
food ingredients 
β-sitosterol RESS tween80 and SDS used to avoid growth and agglomeration mean 200±50 nm [54] 
caffeine RESS needle-like crystals length 1-25 μm [57] 
cocoa butter RESS Form V crystals 0.3-1.5 mm [56] 
stigmasterol RESS 





 2-3 μm 
[88] 
d/L = diameter/length 
D90 = equivalent volume diameter 
below which is 90% particle diameter  
EtOH = ethanol 
HCFC = chlorodifluoromethane 
HYAFF = hyaluronan total benzyl ester 
L/d = length/diameter 
MeOH = methanol 
PDLLA = poly D,L-lactide 
PGA = polyglycolic acid 
PGMA = poly glycidylmethacrylate 
PLLA = poly L-lactide 
PMMA = polymethyl methacrylate 
SDS = sodium dodecyl sulphate 
THF = tetrahydrofuran 
2.1.2 SCF as antisolvent 
Supercritical antisolvent precipitation has been proposed using various acronyms, but the 
process is substantially the same in all the cases (Table 1). A liquid solution contains the 
solute to be micronized. At the process conditions, the supercritical fluid should be 
completely miscible with the liquid solvent, whereas the solute should be insoluble in the 
SCF. As a rule, SC-CO2 has been used. Therefore, contacting the liquid solution with the 
SCF induces the formation of a solution and produces supersaturation and precipitation of 
the solute. The formation of the liquid mixture is very fast due to the enhanced mass 
transfer rates that characterize the supercritical fluids and, as a result, micro- and nano-





process arrangements. The most significant differences are, however, related to whether the 
process operates in batch or in semi-continuous mode [9]. In batch operation (GAS: Gas 
AntiSolvent) the precipitation vessel is loaded with a given quantity of the liquid solution 
and the supercritical antisolvent is added until the final pressure is obtained. In semi-
continuous operation (SAS: Supercritical AntiSolvent) the liquid solution and the 
supercritical anti-solvent are continuously delivered to the precipitation vessel in co-current 
or counter-current mode. An important role is also played by the liquid solution injection 
device [89-91]. The injector is designed to produce liquid jet break-up and the formation of 
small droplets to produce a large mass transfer surface between the liquid and the gaseous 
phase. Several injector configurations have been proposed and patented in the literature 
[92-97]. A new kind of injector has been recently proposed [98-100]. It consists in the tube-
in-tube injector already proposed by other authors [22,94], but in this case SC-CO2 flows in 
the inner tube and the liquid solution in the outer annulus, whereas in the traditional way it 
is the opposite. Spiral slots, inclined at a 45° angle, are added onto the annulus to improve 
the mixing of SC-CO2 that is forced to contact on the thin swirl film and the solution. 
A high-pressure vapour-liquid equilibrium (VLE) and mass transfer between the liquid and 
the SCF also play a relevant role in SAS. Particularly, VLEs of the ternary system solute-
solvent- antisolvent and the position of the operating point in SAS processing with respect 
to these VLEs, can be decisive for the success of the process [22]. When the supercritical 
antisolvent micronization process is performed properly, it is possible to obtain 
nanoparticles (diameter <200 nm), submicro- (diameter 0.2-1 μm) and microparticles 
(diameter 1-5 μm), hollow micrometric particles (balloons, diameter >10 μm) and crystals 
by varying the operating conditions. The formation of a single supercritical phase is the key 
step for the successful production of nanoparticles [101]. The formation of very large 
crystals observed in some cases [9] may be connected to SAS precipitation from a liquid-
rich phase due to a modification of the shape and the extent of the miscibility gap. When 
two phases are present, different morphologies that can be related to the precipitation from 
a liquid rich phase (crystals) and an SCF-rich phase (amorphous particles) can be observed 
simultaneously. The relative quantities of precipitates correlate to the partition factor of the 
solute between the two phases. It is interesting to note that in some cases semi-crystalline 
and crystalline particles can be obtained, in my opinion, because the crystallization rate of 
the compounds is high and the crystallization time is shorter than the characteristic time of 
the SAS process. Another kind of micrometric particles, called balloons, have been 
produced by SAS at homogenous subcritical conditions [102]. Balloons are particles with 
the size of 10-180 μm and with hollow or porous interiors. They can find application in the 





antisolvent at the end of the precipitation process is also fundamental to avoid the 
condensation of the liquid phase that otherwise rains on the precipitate modifying its 
characteristics. 
When the injection of the liquid solution is properly performed, the limits of the SAS 
process are in the difficulty of predicting VLE modifications induced by the presence of 
solute on the binary liquid-SCF system. Very complex phase-behaviours can be produced. 
In the simplest case the shift of the mixture critical point (MCP) towards higher pressures 
can be observed. In the case of a large increase of the MCP pressure, very large pressures 
will be required to obtain a single-phase system and the successful production of 
nanoparticles [103]. 
The supercritical antisolvent technique has found many applications in the pharmaceutical 
field, mainly because of the possibility of producing a powder with controlled particle size 
and distribution using a non-expensive process, solvents already in use in the 
pharmaceutical protocols and a non-polluting antisolvent. A large selection is reported in 
Table 3. In addition to pharmaceuticals, proteins are also shown in Table 3 mainly because 
of their various applications as drugs for treatment of life-threatening and chronic diseases 
[36]. Different solvents that have affinity with SC-CO2 can be used, which increases the 
possibility of applying the technique to several compounds with different characteristics. 
The chosen solvent also has an influence on the final product, and some solvents are more 
successful than others, mainly due to their interaction with the solid compound. Due to 
their optimal interaction with SC-CO2, the most used solvents are dimethyl sulfoxide 
(DMSO) and N-methyl pyrrolidone (NMP). Other commonly used solvents are methanol 
(MeOH), acetone, toluene and ethyl acetate (EtAc) (see Table 3). Ethanol (EtOH) is less used 
mainly because, due to its chemical structure and the possibility to easily form hydrogen 
bridges, it interacts strongly with the solid compound dissolved in it and modifies the VLE 
solvent-antisolvent-solute in an unpredictable way. Water cannot be used as solvent 
because of its relatively low solubility in SC-CO2. Consequently, it is difficult to micronize 
hydrophilic compounds by SAS. Moreover, adding even a small quantity of water into a 
solvent used in the SAS technique relevantly changes the VLE solvent-antisolvent. For 
example, the addition of small amounts of water into a DMSO solution produces an 
enlargement of the area of operation in the VLE diagram. The two-phase region is enlarged, 
the MCP is moved to higher pressures and, consequently, the region of gas miscibility 
below the MCP is enlarged [104]. 
To micronize also water-soluble compounds, some authors have tried to modify the SC-CO2 





of the SCF [105-107], but the results are, as a rule, mainly primary particles in the range 100-
500 nm, agglomerated in large aggregates of several tenths of microns. Particles were 
produced only in few cases [108], and up to 19 wt% of EtOH in CO2 was used as modifier. 
At such compositions the mixture solvent-antisolvent-cosolvent is not in supercritical 
conditions, but in the conditions of an expanded liquid [109]. 
Because of their limited solubility in SC-CO2, supercritical antisolvent micronization 
techniques have found many applications in polymers and bio-polymers [13]. The major 
results obtained in the micronization of bio-polymers and bio-compatible polymers are 
reported in Table 3. These bio-polymers can be used in pharmaceutical applications as drug 
carriers, or in food processing to stabilize some labile compounds used in nutraceutical and 
functional foods production [110]. 
The limit in the application of this technique to food ingredients is that chlorinated solvents 
(e.g. dichloromethane) and other solvents classified as Class 3 in the Federal Register of the 
International Conference of Harmonization [111] (e.g. DMSO) are used to dissolve the 
untreated compound. They are not accepted by the European Directive concerning the use 
of additive and other substances in food [7,112-114] and the purity of food additives [115]. 
However, successful micronizations have been performed using EtOH and spherical 
connected amorphous particles have been obtained in the case of soy lecithin phospholipids 
[116,117] and orthorhombic crystals in the case of ginkgo ginkgolides [118]. 
Chattopadhyay et al. [119,120] proposed a batch supercritical antisolvent (GAS) 
micronization process enhanced with the addition of a vibrating surface in the precipitation 
vessel, with the aim to reduce the size of the final particles. The technique was named 
Supercritical AntiSolvent with Enhanced Mass transfer (SAS-EM). They produced 
griseofulvin (antifungal, antibiotic) particles as small as 130 nm and lysozyme (enzyme) 
particles of about 190 nm. 
From the Table 3 it can be noted that the control of particle size is not an easy task. For the 
majority of compounds, only a specific typology of particles (e.g. nanoparticles, 
microparticles, crystals and balloons) was obtained for each one, showing that it is still not 
well known how to modulate the operating conditions to get different typologies of 
particles for the same compound. Although many chemical compounds with different 
characteristics have been processed by supercritical antisolvent techniques, indications 
cannot be found. The way to proceed in the case of new compounds is still to study the 
system of interest, following the results obtained with similar systems. 
Some authors have studied SAS process mechanisms to give an interpretation of the results 





interactions among thermodynamics, mass transfer, jet hydrodynamics and nucleation 
kinetics. Werling and Debenedetti [16,17] proposed a mathematical model based on the 
mass transfer between solvent and antisolvent in a single droplet of solvent considering the 
influence of density and diffusivity at subcritical [16] and supercritical conditions [17]. 
Rantakylä et al. [19] studied the influence of the initial droplet size on the particle size of the 
final formed solid product. Perez et al. [121-123] in the case of polymers, at conditions of 
complete miscibility between the organic solvent and CO2, proposed that droplets are the 
result of the formation of a liquid-liquid phase split. Jarmer et al. [20] proposed a nucleation 
and growth rate model for PLLA (poly L-lactide) related to the characteristics of the 
suspension density and suggested the importance of the role of secondary nucleation. 
Only few authors considered the influence of the thermodynamics and phase behaviour of 
the system on particle morphology and size [22,103,124,125] and, due to the difficulties in 
the construction of ternary diagrams, in many cases some authors considered the 
corresponding binary diagrams solvent-CO2 and neglected the influence of the solute in the 
system [126]. However, such approximation cannot be applied when the presence of the 
solute largely modifies the VLEs [22,103,125]. 
The influence of fluid dynamics on particle morphology is also a relevant aspect in the SAS 
process, because the atomization produces large surfaces between the liquid and the fluid 
phase. Some authors have studied the fluidodynamics of solutions at the exit of the injector 
in the supercritical medium [15,127,128], while others have studied the characterization of 
the jet break-up and atomization in supercritical conditions [91,129,130]. 
Elvassore et al. [131] performed a theoretical investigation of mass transfer at high pressure 
for ternary systems and developed a mathematical model for mass transfer between a 
droplet of a polymeric organic solution and a compressed gas antisolvent under conditions 
of miscibility [18]. Martín and Cocero [132] tried to combine the description of all the 
physical phenomena relevant for the SAS process into a single model. Phase equilibrium, 
mass transfer, jet hydrodynamics and crystallization kinetics were considered. The phase 
equilibrium data and solid-fluid interfacial tension parameters were used for the 
calculations. The results of the model were compared to experimental results of ascorbic 
acid, but the model proved to be descriptive rather than predictive. Furthermore, the 







Table 3. Pharmaceutical compounds, bio-polymers and food ingredients micronized by SCF-
based techniques. SCF used as antisolvent. 
material solvent process/notes results/observations particle size ref 
pharmaceuticals 







nanometric irregular particles 
interconnected <100 nm [107] 
amoxicillin NMP SAS amorphous spherical particles mean 0.2-12 μm [134,135] 
amoxicillin NMP SAS pilot amorphous spherical particles mode 0.2-0.8 μm [21] 
amoxicillin DMSO, EtOH/DMSO SAS amorphous spherical particles 0.2-1.6 μm [136] 
ampicillin NMP SAS aggregated and separated amorphous spherical particles mean 0.26 μm [137] 





activity of processed 





activity of processed 
antibody 3%   [105] 
ascorbic acid acetone PCA small irregular crystals elongated crystals 
1-4 μm 
mean 30 μm [138] 
atenolol MeOH ASES spherical aggregated particles mean 42.74±20.62 μm [139] 
atenolol EtOH ASES spherical aggregated particles mean 20.84±11.34 μm  [139] 
atenolol iso-propanol ASES spherical aggregated particles mean 16.83±10.60 μm [139] 
β-lactamase water SEDS, CO2+EtOH 
    [92] 
baicalin MeOH SEDS-PA 
rod-like particles 
 
twisted fiber-like particles 
 








17,21-dipropionate acetone GAS 
irregular particles with a more 
defined crystalline structure 
mean 1.8 μm, 
MMAD 7.9 μm [141] 
budesonide DCM ASES same crystallinity of untreated <5 μm [142] 
budesonide DCM PCA spherical particles mean 1-2 μm [143] 
budesonide MeOH SEDS plate-like particles 5–30 μm [144] 
budesonide acetone SEDS smooth irregular spherical particles 1–3 μm [144] 
budesonide DCM ASES crystalline particles D50=6-8 μm [145] 













material solvent process/notes results/observations particle size ref 
pharmaceuticals 
carbamazepine MeOH SEDS crystals, polymorphic forms α, β, γ several tenth μm [148] 
carbamazepine DCM SEDS crystals, polymorphic forms α, β, γ several tenth μm [148] 
carbamazepine acetone GAS needle-like particles mode 31 μm [149] 
carbamazepine acetone GAS needle-like particles, decrease of % of Form III, modification in Form I 
L/d=161.86 μm/
40.35 μm [150] 
carbamazepine DCM GAS 
needle-like particles, decrease of % of 
Form III, modification in Form I, 
partial amorphisation 
L/d=173.36 μm/
38.65 μm [150] 
carbamazepine EtAc GAS needle-like particles, decrease of % of Form III, modification in Form I 
L/d=97.46 μm/3
7.27 μm [150] 
catalase EtOH:water 90:10 ASES   mean 1 μm [151] 
cefonicid DMSO SAS spherical submicroparticles and empty shells 




cefoperazone DMSO SAS submicrometric particles, micropetric particles, large crystals 
mode 0.25-
0.5 μm [125] 








chlorpropamide acetone SAS columnar habit crystals several tenth μm [152] 
chlorpropamide EtAc SAS platy crystals several tenth μm [152] 
cholesterol acetone GAS needle-like and flatted tabular crystals >50 μm [153] 








cilostazol DCM, glacial acetic acid SAS irregular interconnected crystals 
mean 0.90-
4.52 μm [154] 
copper 
indomethacin DMF ASES 
porous spherical particles, 
bipyramidal crystals, spheres made 
of small crystals 
<5 μm or 10-
50 μm [155] 
copper 
indomethacin NMP ASES 
large spheres 
irregular particles  
mean 20 μm 
2-5 μm [155] 
copper 
indomethacin DMSO ASES agglomerates of irregular platelets around 200 μm [155] 
copper 
indomethacin DMF GAS 
rhombic or bipyramidal particles 
depending on the expansion rate 2–100 μm [155] 
copper 
indomethacin NMP GAS clusters of needle-like crystals 50-100 μm [155] 
copper 
indomethacin DMSO GAS clusters of needle-like crystals 50-100 μm [155] 
copper 
indomethacin DMF GAS 
slow expansion: rhombic crystals 
fast expansion: crystals 
mean 50 μm 
mean 20 μm [155] 
cromolyn sodium MeOH ASES amorphous particles 0.1-20 μm [156] 
dexamethasone 
phosphate MeOH SAS-EM coalescing spherical nanoparticles 150-200 nm [157] 





material solvent process/notes results/observations particle size ref 
pharmaceuticals 
fluconazole DCM SAS needle-like crystals,  anhydrate Form I, Form II 
several 
hundred μm [158] 
fluconazole EtOH SAS needle-like crystals,  anhydrate Form II 
several 
hundred μm [158] 
fluconazole acetone SAS needle-like crystals, anhydrate Form I 
several 
hundred μm [158] 
flunisolide DCM ASES different polymorphic form than untreated <5 μm [142] 
flunisolide 
anhydrous MeOH SEDS 
polymorphic particles Form IV,  
Form II, Form IV+ Form III several tenth μm [144] 
flunisolide 
anhydrous acetone SEDS 
polymorphic particles Form III,  
Form I+ Form III several tenth μm [144] 
fluticasone-17-
propionate DCM ASES 
spherical amorphous particles, 
ribbons particles with different 
polymorphic form 





α-glycine, β-glycine and γ-glycine, 
cocoon-like, urchin-like, irregular 
crystals 
>10 μm [159] 
griseofulvin DCM SAS-EM (GAS) needle-like and nanometric particles 
volume-average 
310 nm [119] 
griseofulvin THF SAS-EM (GAS) needle-like and nanometric particles 
volume-average 
310 nm [119] 
griseofulvin acetone GAS 
tetragonal crystals 
 









hydrocortisone acetone SEDS network of needles several hundred μm [161] 
hydrocortisone MeOH SEDS flake-like particles, mixture of flakes and needles several tenth μm [161] 
hydrocortisone MeOH SAS-EM 
needle-like particles 
irregular spherical particles 






acetate DMF ASES crystals mean 5 μm [163] 
insulin DMSO, DMF ASES/GAS spherical aggregated particles D90<4 μm, D10<1 μm 
[164] 
insulin DMSO SAS irregular coalescing particles 1-5 μm [165] 
insulin water SEDS, CO2+EtOH 
spherical particles, 
more or less aggregated 50-500 nm [106] 
insulin EtAc GAS discrete spherical particles,  very narrow PSD 0.3-0.7 μm [166] 
insulin EtOH GAS discrete spherical particles,  very narrow PSD 0.05-0.03 μm [166] 
insulin DMSO, MeOH ASES primary spherical particles aggregate 
primary particles 
0.2 μm [167] 







material solvent process/notes results/observations particle size ref 
pharmaceuticals 
insulin MeOH GAS discrete spherical particles,  very narrow PSD 0.2-0.7 μm 
[166,
167] 
insulin HFP PCA coalescing spherical nanoparticles mean 50 nm [168] 
insulin EtOH-water ASES   mean 1 μm [151] 
ipratropium 
bromide DMF ASES regular elliptical particles 
aerodynamic 
diameter 0.6-3 μm [169] 
lactose water SEDS, CO2+MeOH 
particle morphology depending on 





crystals, monohydrate changes the 
hydratation mean 100 μm [171] 
lobenzarit disodium water ASES, CO2+EtOH 
  0.2-0.6 μm [172] 
lysozyme DMSO SAS irregular coalescing particles 1-5 μm [165] 
lysozyme water SEDS, CO2+EtOH 
spherical particles,  
more or less aggregated 500 nm [106] 







discrete spherical particles, 







discrete monodisperse spherical 







discrete spherical particles,  
very narrow PSD 0.05-0.25 μm 
[166,
167] 
lysozyme DMSO GAS discrete monodisperse spherical particles 0.05-0.07 μm 
[166,
167] 
lysozyme DMSO GAS discrete monodisperse spherical particles 0.01-0.05 μm 
[166,
167] 
lysozyme DMSO GAS amorphous spherical particles,  more or less agglomerated 
200-300 nm, 
mean 180 nm [173] 
lysozyme water 
SCF-drying, 









lysozyme DMSO, water SEDS irregular agglomerated particles primary particles 1-5 μm 
[174,
175] 
lysozyme DMSO SAS-EM (GAS) 
irregular separated particles or 
aggregated mean 190 nm [120] 
lysozyme DMSO ASES aggregated nanospheres <100 nm [176] 
methylprednisolone THF ASES, CO2 or ethane crystalline particles mean 5 μm [163] 
myglobin DMSO ASES spherical agglomerated particles 0.03-0.4 μm [167] 
myglobin DMSO GAS spherical polydisperse particles 0.03-0.4 μm [166,167] 





material solvent process/notes results/observations particle size ref 
pharmaceuticals 
nicotinic acid absol EtOH SEDS  0.4-0.75 μm [177] 
nicotinic acid MeOH SEDS crystalline smooth tabular particles 1-5 μm [178] 
nimesulide CHF, DCM SAS needle and thin rods shaped crystals Form I   [179] 
nimesulide acetone SAS needle and thin rods shaped crystals, meta-stable Form II   [179] 
n-trimethylchitosan DMSO-water PCA coalescing particles and spherical microparticles 1-10 μm [104] 
oxeglitizar EtOH+CHF, EtOH SAS 
needle-like crystals, polymorphic 
form A >50 μm [180] 
oxeglitizar THF, DCM SAS needle-like crystals, polymorphic form A, traces form B >50 μm [180] 
oxeglitizar EtOH/THF (50:50), EtOH SAS 
needle-like crystals, polymorphic 
form A and form B >50 μm [180] 
paracetamol 
(acetaminophen) EtOH SEDS irregular prismatic crystals 10–15 μm [181] 
paracetamol 
(acetaminophen) EtOH PCA 
irregular crystals 
small and elongated 
mean 2 μm 
mean 30 μm [138] 
paracetamol 
(acetaminophen) EtOH SEDS irregular crystals 3-20 μm [182] 
paracetamol 
(acetaminophen) acetone PCA irregular squared particles average 2 μm [183] 
paracetamol 
(acetaminophen) acetone GAS irregular particles 90-250 μm 
[183,
184] 
p-HBA MeOH ASES rhomboidal platelets length 3-10 μm [176] 
p-HBA acetone ASES needle-like crystals length>30 μm [176] 
p-HBA EtAc ASES rod-like crystals length>30 μm [176] 
phenantrene toluene GAS platelet-shape particles formed by agglomerated crystals 160-540 μm [185] 
phenantrene toluene GAS mono and bimodal PSD mean 21-210 μm [186,187] 
prednisolone acetate acetone ASES   mean 1 μm [188] 
prendisolone DCM ASES decrease of degree of crystallinity <5 μm [142] 
RhDNase water SEDS, CO2+EtOH 
spherical separated particles 50-500 nm [106,189] 
rifampicin DMSO SAS 
amorphous particles, 
coalescent nanometric 
spherical separated micrometric 




rIgG water SEDS, CO2+EtOH 
decrease of biological activity 50%   [191] 
salbutamol MeOH + acetone SEDS   0.5 μm [177] 
salbutamol sulphate DMSO SAS 












material solvent process/notes results/observations particle size ref 
pharmaceuticals 
salmeterol xinafoate MeOH, acetone 
SEDS, 
CO2+MeOH 
  1-10 μm [92] 
salmeterol xinafoate MeOH, acetone ASES   1-10 μm [177] 
salmeterol xinafoate MeOH SEDS needle-like particles   [177] 
salmeterol xinafoate acetone SEDS platelet-like particles   [177] 
salmeterol xinafoate EtOH SEDS whilst habit crystals 3-17 μm [194] 
salmeterol xinafoate acetone SEDS blade-like habit crystals, Form I, Form II 3-17 μm [194] 
salmeterol xinafoate MeOH SEDS platelet-like crystals 98% mean 0.5-10 μm [195] 
sulfamethizole acetone, DMF SAS-EM tubular habit platy habit 
140-220 μm 
29-56 μm [196] 
sulfathiazole acetone SEDS Form I crystals amorphous spherical particles 
>10 μm 
<2 μm [197] 
sulfathiazole MeOH SEDS 
Form I (fused lumps), Form III (flat 
elongated hexagons), Form IV 
(prismatic solids), and their mixtures 
>20 μm [197] 
sulfathiazole acetone SAS prismatic crystals >750 μm [152] 
sulfathiazole MeOH SAS needle-like, tabular crystal habit >750 μm [152] 
terbutaline sulphate EtOH, MeOH, water SEDS 
amorphous, crystals, form A, form B, 
monohydrate 3-10 μm [198] 
terbutaline sulphate EtOH/DMF ASES agglomerate and separate spherical particles 200-300 nm [199] 
tetracycline NMP SAS needle-like particles irregular amorphous particles 
0.6-0.8 μm 
150 nm [134] 
tetracycline THF SAS-EM (GAS) very fine particles, narrow PSD mean 125 nm [200] 
theophylline EtOH/DCM SAS lamellar crystals and rosette crystals L/d=5-300 μm/ 1-100 μm [201] 
triamcinolone 
acetonide DCM ASES decrease of degree of crystallinity <5 μm [142] 
trypsin DMSO SAS irregular coalescing particles 1-5 μm [165] 
bio-polymers 
ALAFF DMSO GAS   0.8 μm [202] 
β-PLLA-co-PDLLA-
co-PGA 62.5:12.5:25 DCM+TFE ASES 
spherical separated particles, semi-
crystalline D50<10 μm [203] 
dextran DMSO PCA spherical particles,  mono and bimodal PSD 
several nm-
tenth μm [121] 
dextran DMSO SAS spherical particles mean 125-150 nm [204] 
ethylcellulose DCM+DMSO SAS spherical coalescing particles mean 5 μm [205] 
HPMA DMSO SAS spherical particles 100-200 nm [204] 
HPMC, PVP EtOH-DCM, MeOH/CO2 
SEDS microspheres <1 μm [147] 
HYAFF 11 DMSO GAS   mean 0.6 μm [202] 





material solvent process/notes results/observations particle size ref 
bio-polymers 
HYAFF 11 DMSO SAS agglomerated spheres 15-20 μm [83] 
HYAFF 11 DMSO SAS submicronic particles   [206] 
HYAFF 11 p75 DMSO GAS   mean 0.8 μm [202] 
HYAFF 11p75 DMSO SAS submicronic particles   [206] 
HYAFF 11p80 DMSO SAS submicronic particles   [206] 
HYAFF 302 DMSO SAS submicronic particles   [206] 
HYAFF 7 DMSO GAS   mean 1 μm [202] 
inulin DMSO SAS spherical particles connected by humidity bridges <1 μm [204] 
PCL acetone:DCM:isopropanol SEDS 
mixture of separated and 
agglomerated particles 25-85 μm 
[207,
208] 
PDLLA acetone+EtAc SEDS, CO2+N2 
spherical nanoporous particles 9-10 μm [207,208] 
PDLLA-co-PGA 
(50:50) DCM+TFE ASES 
irregular agglomerated particles, 
amorphous D50<120 μm [203] 
PDLLG EtAc:acetone:isopropanol SEDS spherical separated particles 




PHBV DCM SAS 
irregular or spherical particles, 
aggregated or separated, 
disomogeneity of mw 
mean 3-9 μm [209] 
PLLA DCM ASES spherical particles 1-10 μm, 10-30 μm [210] 
PLLA DCM GAS spherical and irregular particles 0.5-3 μm [129] 
PLLA DCM PCA spherical and elliptical particles <3 μm [211] 
PLLA DCM ASES ovoidal microspheres with a smooth to slightly rough surface mean 10-12 μm [212] 
PLLA DCM ASES spherical separated particles and particles with cracks and holes mean 6-50 μm [213] 
PLLA DCM ASES spherical semicrystalline particles D10=1.76 μm, D90=6.78 μm 
[214] 
PLLA DCM:acetone:isopropanol SEDS 
mixture of spherical particles and 
irregular particles 7-10 μm 
[207,
208] 
PLLA DCM SAS spherical particles 1-2 μm, mean 1.4 μm [204] 
PLLA CHF PCA spherical agglomerate particles mean 1.6 μm [127] 
PLLA DCM SAS spherical particles or fibres 1-5 μm [215] 
PLLA DCM ASES discrete microspheres <2 μm [176] 
PLLA DCM SAS fibres and/or microspheres mean 1–3 μm [130] 
PLLA DCM PCA spherical particles mean 193±19 μm [96] 
PLLA DCM PCA connected nanoparticles spherical wrinkling microparticles 
0.1-2 μm 
5-50 μm [122] 
PLLA DCM CTAR elliptical regular particles 1-3 μm [97] 
PLLA EtOH/DCM SEDS spherical particles 1.1-3.6 μm [133] 
PLLA DCM, THF,  1-4 dioxane ASES spherical particles 0.6-2.3 μm [216] 





material solvent process/notes results/observations particle size ref 
bio-polymers 
PMMA acetone GAS fractionation of different molecular weights   [217] 
PVA-PLLA DCM ASES spherical semicrystalline particles D10=1.21 μm, D90=7.29 μm 
[214] 
food ingredients 
albumin water SEDS, CO2+EtOH 
  50-500 nm [106] 
β-carotene DCM GAS irregular particles <1 μm [218] 
β-carotene EtAc GAS platelet-like crystals 2-10 μm [218] 
β-carotene DCM SEDS-PA irregular particles, increase of purity in the particles 0.4-2.9 μm [100] 
bixin DCM SEDS-PA needle-like particles d/L=0.3-1.1 μm/ 2-16 μm [98] 
ginkgo ginkgolides EtOH SAS orthorhombic crystals L/d=10-200 μm/ 3-50 μm [118] 
lycopene DCM SAS needle-like particles 10-80 μm [219] 
maltose water SEDS, CO2+EtOH 
free flowing white powder  [170] 
soy lecithin EtOH SAS partly coalescing spherical particles 1-10 μm, 5-45 μm [116] 
soy lecithin EtOH SAS partly coalescing spherical particles 10–40 μm [117] 
sucrose water SEDS, CO2+EtOH 
free flowing white powder  [170] 
tartaric acid acetone PCA plate-like crystals 10-20 μm [220] 
tartaric acid MeOH+EtOH PCA plate-like, needle-like crystals 25-45 μm [220] 
tartaric acid EtOH PCA irregular crystals 35-60 μm [220] 
trehalose water SEDS, CO2+EtOH 
free flowing white powder  [170] 
ALAFF = benzyl ester of alginic acid 
CHF = chloroform 
d/L = diameter/length 
D10 = equivalent volume diameter 
below which is 10% particle diameter  
D90 = equivalent volume diameter 
below which is 90% particle diameter  
DCM = dichloromethane 
DMF = dimethylformamide 
DMSO = dimethyl sulfoxide 
EtOH = ethanol 
EtAc = ethyl acetate 
Fab = fragment antigen binding  
Fv = fragment variable 
HFP=1,1,1,3,3,3-hexafluoro-2-propanol 
HPMA = hydroxpropylmethacrylic acid 
HPMC = hydroxypropyl methylcellulose 
HYAFF = hyaluronan total benzyl ester 
HYAFFp = hyaluronan partial benzyl ester 
L/d = length/diameter 
L/w = length/width 
MeOH = methanol 
MMAD = mass median aerodynamic 
diameter 
NMP = N-methyl pyrrolidone 
PCL = polycaprolactone 
PDLLG = poly D,L-lactide-co-glycolide 
PDLLA = poly D,L-lactide 
PGA = polyglycolic acid 
PHBV = polyhydroxybutyrate-valerate 
PLLA = poly L-lactide 
PSD = particle size distribution 
PVP = polyvinyl pyrrolidone 
PVA = polyvinyl alcohol 
TFE = 2,2,2-trifluoroethanol 
THF = tetrahydrofuran 
2.1.3 SCF as solute 
In the PGSS (Particles from Gas Saturated Solution) process, a compressible gas (i.e. CO2) is 
dissolved under pressure in a melted or liquefied substance acting as a solute in the 
process. Polymers are the best candidates for this kind of process because the capacity of 





temperatures are often required to liquefy other compounds to be micronized. This gas-
saturated solution is later expanded with consequent supersaturation and fine particles 
precipitation [222]. This method shows some advantages and some disadvantages over 
other techniques based on SCF. When compared with RESS, the consumption of CO2 is 
lower by three orders of magnitude for PGSS. When compared with SAS, no organic 
solvents are needed for PGSS. In the case of polymers, the knowledge of the pressure-
temperature behaviour gives information about the pressure needed to melt the substance 
to be micronized and form a liquid phase at a given temperature, and allows to calculate its 
composition [44]. Some examples of applications of PGSS are reported in Table 4. 
The high temperatures often required may lead to some chemical changes of the 
compounds during processing by PGSS [223,224]. Hence, this technique is not suitable for 
pharmaceutical compounds. Polymers and bio-polymers can be easily treated by PGSS, but 
the results obtained are mainly aggregated materials [225]. Not many applications of this 
technique to food ingredients are found in literature. Münüklü and Janksen [226] proposed 
the PGSS process with the name Supercritical Melting Micronization process (ScMM) for 
the micronization of edible fats. Solid microparticles and hollow microparticles of 
rapeseed 70 were produced using a continuous operated pilot plant. Rapeseed 70 is 
hardened rapeseed oil with a melting point of 70°C, used in the food industry as an 
emulsifier e.g. in margarine production. Therefore, it is important to have a powder with 
the morphology and size of micro particles. Moreover, hollow particles of edible fats are 
suitable for encapsulation. 
Theoretical investigation of PGSS is at the beginning, and few papers have been published 
in this area to date. An exhaustive description of the PGSS process demands the 
investigation of many different mechanisms and phenomena, including supercritical fluid 
thermodynamics, jet-spray hydrodynamics, droplet fluid dynamics, crystallization kinetics, 
bubble formation and droplet coalescence. Elvassore et al. [227] have investigated PGSS 
thermodynamics. Li et al. [228] have considered the nozzle hydrodynamics in the PGSS 
process. They also developed a general model based on the atomization and the 
crystallization mechanisms that considers both the melt crystallization and the gas-solution 
crystallization. Strumendo et al. [229] investigated the behaviour of an isolated gas-
saturated solution droplet in a gaseous environment and developed a mathematical model 






Table 4. Pharmaceutical compounds, bio-polymers and food ingredients micronized by SCF-
based techniques. SCF used as solute. 
material process/notes results/observations particle size ref 
pharmaceuticals 
cyclosporine A PGSS amorphous spherical particles mean 4.5 μm [72] 
nifedipine PGSS irregular porous particles mean 15-30 μm [223,224] 
bio-polymers 
catalase PGSS porous macroparticles   [225] 
galactosidase PGSS porous macroparticles   [225] 
PLA PGSS porous macroparticles   [225] 
PLGA PGSS porous macroparticles   [225] 
food ingredients 
rapeseed 70 ScMM empty balloons, form α, 84% crystallinity 8-90 μm [226] 
PLA = poly-lactide PLGA = poly D,L-lactide-co-glycolide  
2.1.4 SCF as co-solute 
The techniques that use CO2 as co-solute have something in common with the 
micronization by spray-drying: the SCF and the solution are intimately mixed and then 
sprayed in a drying atmosphere. These SCF-based micronization techniques are very 
interesting because they can be applied to water-soluble compounds difficult to handle 
with the other SCF techniques without excluding the possibility of using other organic 
solvents. The relatively low temperatures used allow to treat thermolable compounds as 
well. 
Supercritical Assisted Atomization (SAA) is a recent process [23,230] in which the SCF acts 
as an atomizing medium. Atomization, also assisted by an inert gas, is generally used in the 
spray drying of solutions. The innovative aspect of the SAA process is the solubilization of 
SC-CO2 in the liquid solution formed by the solvent and the (solid) solute, and the 
subsequent atomization of the gas-solid-liquid mixture using a thin wall nozzle. Indeed, 
gases are released slowly from the liquid phase and their contribution to a two-step 
atomization is not relevant [231]. Gases at supercritical conditions are released from the 
liquid phase by a faster process [230]; therefore, SC-CO2 can improve the atomization 
process, contributing to a two-step atomization. The operating conditions that are 
characteristic of the SAA process are the formation of a single, expanded liquid, phase in 
the mixing device. When SAA is properly conducted, two atomization processes take place: 
the first one is the production of primary droplets at the exit of the nozzle by pneumatic 
atomization and the second one is the destruction of these droplets by the fast release of 
CO2 from the internal of the droplet (decompressive atomization). Depending on the 





crystalline particles have been produced [232]. The SAA process has been successfully 
performed using water, organic solvents with relatively low boiling points (EtOH, MeOH, 
acetone) and mixtures of them. Solvents with high boiling points, typically used e.g. in SAS 
micronization (i.e. DMSO, NMP, toluene) cannot be used because of the difficulty of 
removing them during precipitation. The limit of this process is that the smallest particles 
produced depend on the dimensions of the smallest secondary droplets generated (one 
droplet-one particle process). The dimensions are connected to the classical parameters that 
control droplet dimensions during atomization: surface tension, viscosity and quantity of 
SCF dissolved in the liquid. The scale-up of the process has been performed, based on the 
geometrical similitude, on a semi-continuous plant with a precipitator and a saturator 
volume that is five fold the laboratory scale (14 dm3 and 0.15 dm3 respectively) [233]. 
CAN-BD (CAN-Bubble Drying) has similar features as SAA [234], that is, a two-phase 
mixture of CO2 and the formation of a liquid solution [235]. The key principle is different 
from SAA, because the CO2 is not solubilized in the solution but contacts the liquid in a 
near zero volume tee (<1 μL) with a short residence time. 
Li et al. [236,237] used a process called Supercritical Fluid Expansion Depressurization 
(SFED) to produce microparticles of pharmaceutical compounds. The apparatus and the 
process are identical to the SAA technique [230], the micronized products and the operating 
conditions used have also been reproposed. No additional contribution can be found. 
In another process, called Depressurization of an Expanded Liquid Organic Solution 
(DELOS) [238], a compressed gas, CO2 not necessarily at supercritical conditions, is used 
for the production of micro- and submicro crystalline particles from an organic solution. 
The compressed CO2 is solubilized, at a given pressure and temperature, in the organic 
solution of the solute to be crystallized. It has the role to produce, by Joule-Thomson effect, 
a homogeneous sub-cooling of the solution with supersaturation and solid particles 
precipitation [239]. Up to know, the process has been successfully applied to inorganic 
colorants [238,239] and some preliminary experiments on fatty acids and some drugs have 
been reported in some conference proceedings [240]. 
These micronization techniques are relatively new, but many applications of SAA and 
CAN-BD on pharmaceutical compounds can already be found (Table 5). In all cases, 
spherical particles are produced with different degrees of crystallinity, mainly because of 
the operating temperature used. An interesting application can be found in those 
compounds that can be used as carriers or excipients in foods due to their high solubility in 
water or their particular conformations. Examples of this are cyclodextrins [241], lactose 





micronized as spherical amorphous micrometric particles (Table 5). No modeling studies on 
these techniques are present in literature yet. These processes seem to be very promising, 
and in the future, when more data are available and the mechanism of particle formation is 
clearer, the translation into mathematical models will be performed. 
Table 5. Pharmaceutical compounds, bio-polymers and food ingredients micronized by SCF-
based techniques. SCF used as co-solute. 
material solvent process/notes results/observations particle size ref 
pharmaceuticals 
α-cyclodextrin water SAA crystalline spherical particles 95% 0.1-5 μm [241] 
α-lactose water CAN-BD spherical aggregated particles mean 1 μm [242] 
amphotericin B EtOH CAN-BD irregular particles mean 1 μm [245] 
ampicillin buffered water (pH7) SAA 
amorphous spherical 
particles mean 0.8-5.6 μm [246] 
budesonide EtOH CAN-BD spherical particles mean 1 μm [245] 
carbamazepine MeOH SAA micronic needle-like particles several tenth μm [230] 
cromolyn 
sodium water CAN-BD 
spherical irregular 
coalescing particles 
number-average 0.58 μm, 
volume-average 0.40 μm [242] 
dexamethasone acetone SAA amorphous spherical particles <3 μm [230] 
DL-alanine   CAN-BD   0.3-0.5 μm [234] 
erythromycin MeOH, EtOH SAA spherical particles 
<3 μm, 88% particles 
volume 1-3 μm [247] 
erythromycin acetone SAA spherical particles and coalescing particles <3 μm [247] 
erythromycin EtOH SFED spherical particles and coalescing particles <3 μm [236] 
griseofulvin acetone SAA spherical semicrystalline particles mean 0.5-2.5 μm [248] 
HMR1031 MeOH SAA amorphous spherical particles MMAD 1.6-4 μm [249] 
hydroxypropyl-
β-cyclodextrin water SAA 
amorphous spherical 
particles 95% 0.1-5 μm [241] 
LDH water CAN-BD 85% activity lost   [250] 
lysozyme water CAN-BD 
aggregates, divided when 
sucrose and tween80 used 
as additive, amorphous 
powder 
1–3 μm [250] 
naproxen 95%EtOH: 5% water CAN-BD 
irregular coalescing 
particles 
primary particles 0.91 μm, 
agglomerates 0.5-5 μm [245] 
rifampicin MeOH SAA separated deflated spherical particles <3.2 μm, mean 0.7-1.8 μm [251] 





material solvent process/notes results/observations particle size ref 
pharmaceuticals 
salbutamol 
sulphate water CAN-BD spherical particles 
number-average 0.70 μm, 
volume-average 0.95 μm [242] 
terbutaline water SAA very regular and homogeneous particles >99% 1-4 μm [252] 
tetracycline water SAA separated spherical particles <2.4 μm, mean 0.5-1.3 μm [251] 
tetracycline water/ EtOH SFED 
approximately spherical 
particles 1-3 μm, mean 1.3-1.5 μm [237] 








spherical particles with 
decreased degree of 
crystallinity 
99% 0.1-1.5 μm [243] 
PLLA DCM SAA spherical particles 1.5-3.5 μm [244] 
PMMA acetone SAA spherical particles, decrease of the Tg 0.05-1.6 μm [244] 
food ingredients 
palmitic acid EtOH CAN-BD leaf shaped coalescing particles 0.43-0.65 μm [245] 
DCM = dichloromethane 
EtOH = ethanol 
MeOH = methanol 
MMAD = mass median aerodynamic diameter Tg = glass transition temperature 
2.2 Polymorphic modifications induced by SCF 
In the last five years, one development in the application of SCF-based micronization 
techniques has been the production of particles not only with controlled particle size and 
distribution, but also with controlled crystal habit or polymorphic form. 
A solid compound can exist in several forms, either as crystalline or amorphous. Gross 
structural modifications such as polymorphism and solvate formation are notably common 
for certain groups of drugs. Polymorphs are crystalline phases containing the same 
molecules or ions but having different conformations and/or packing arrangements in the 
solid-state. Solvates are also crystalline phases and are formed when solvent molecules are 
present in the crystal lattice, leading to molecular adducts with the host molecules. If the 
solvent is water, the molecular adducts are termed hydrates [253]. The crystal habit is the 
external shape of a crystal. An identical compound can have many crystal habits due to the 
different growth rate of each crystal surface. The habit does not reflect the internal structure 
of a crystal. A crystal that has an identical internal space lattice can show different crystal 
habits. If a pharmaceutical compound that has only one polymorphic form undergoes a 





Polymorphic forms can have remarkably different physical properties in pharmaceutical 
compounds. These can include solubilization rate and melting point, which result in 
different stability and bioavailability of drug products. If a mixture of polymorphs occurs in 
a pharmaceutical formulation, the quantitative control of crystallization is required to 
ensure a fixed proportion of forms. In addition, solid-state recrystallization phenomena, 
which may have conversion times between seconds and years, have to be suppressed to 
maintain integrity during product shelf-life. It should be remembered, however, that 
processing techniques such as milling, drying and compression can also introduce 
polymorphic modifications and transformation [253]. The effect of a solvent or solvent 
mixture on the formation of stable and unstable polymorphs is well known [254,255]. 
In some food applications, the polymorphic form might be important when specific 
characteristics are required. An example is cocoa butter, which exists as six different 
polymorphic forms identified with roman numerals in order of their different melting 
point. Different polymorphs give different consistencies to the final product (chocolate). 
Form V is the polymorph preferred to the others, because it gives the chocolate a better 
structure and taste. The other forms feel too sticky or thick in the mouth. Form VI is 
associated with fat bloom, a condition where the cocoa butter separates out during storage. 
Although Form V is the best tasting polymorph of cocoa butter, Form VI is the most stable 
[256]. Food scientists in the chocolate industry seek to develop techniques that lead cocoa 
butter to solidify in the desirable Form V polymorph. 
Several studies have showed that the dramatic change in solid morphology after processing 
by SCF is not only related to particle size and distribution, particle shape and porosity, but 
sometimes the crystal pattern is modified as well. SC-CO2 can be a suitable solvent for 
producing crystallographically pure phases when mixtures of polymorphs of a particular 
pharmaceutical compound are involved, thus avoiding the use of organic solvents. Using a 
SC-CO2 treatment, a new polymorph of deoxycholic acid was formed [257]. Deoxycholic 
acid crystals were stored in a pressure vessel with SC-CO2, after which new X-ray 
diffraction peaks not found in the bulk deoxycholic acid crystal were observed. The crystals 
obtained were found to be a metastable form of deoxycholic acid. Equimolar powder 
mixtures of the two carbamazepine polymorphs (Form I, Form III) were submitted to 
treatment with SC-CO2 at 350 bar and 55°C either under a dynamic flow or under static 
conditions [258]. There was an enrichment of the mixture in terms of Form III, essentially 
due to a conversion of Form I via solubilization in SC-CO2 followed by re-crystallisation of 





The RESS technique has been the most successful SCF technique for producing different 
polymorphic forms of a compound, mainly because the use of different operating 
conditions allows to modulate the density and viscosity of the SCF and reproduce some 
characteristics of organic solvents. This characteristic can also stabilize one specific 
polymorphic form. Examples can be found in Table 2 [56,67,68]. 
Using supercritical antisolvent techniques some examples of production of microparticles 
with different polymorphic forms can be found, as reported in Table 3. In some cases, they 
are obtained by varying the operating conditions, mainly the injection flow rate and the 
operating temperatures, which have a great influence on the growth of the nuclei during 
the crystallization [148,158,159,194,197]. In many other cases several polymorphic forms are 
found by varying the solvent used [144,148,150,158,197,198]. The most stable polymorphic 
form is often obtained, but in some cases it is also possible to obtain the same polymorphic 
form of the untreated material. For example, salmeterol xinafoate Form I and Form II 
processed by SEDS retained a high polymorphic purity and distinctly different physical and 
surface properties. Form I is, however, the most stable [259]. The most frequent 
crystallographic changes observed in particles obtained by supercritical antisolvent 
micronization processes are related to the crystal habit of the compound. Indeed, the 
modulating properties of SC-CO2 and the mixture solvent-antisolvent characteristics may 
create an environment particularly favourable to some morphologies 
[155,160,176,177,194,196,220]. 
In some works, additives are used as habit modifiers during SCF crystallization. 
Chloropropamide was crystallized using the RESS process in the presence of urea as a 
polymorph conversion additive [260]. Jarmer et al. [261] proposed the use of poly-sebacic 
anhydride as growth inhibitor of griseofulvin using the SAS process. Griseofulvin crystal 
habit changed from acicular to bipyramidal. Caputo and Reverchon [262] proposed the use 
of urea as habit modifier of sulfathiazole precipitated by SAS from an acetone solution. In 
the presence of urea the sulfathiazole habit changed from a plate shape to spherical 
semicrystalline particles with a very narrow particle size distribution and with a mean 
particle size ranging between 0.5 and 1.0 μm depending on the sulfathiazole concentration. 
The examples reported in Table 3 suggest that, among the other SCF micronization 
techniques, the supercritical antisolvent technique is a promising process for the production 





2.3 Novel developments 
This section focuses on specific applications of SCF-based micronization techniques, which 
differ from the micronization of neat particles, and seem to be very promising. The 
micronization techniques already proposed can be used more or less successfully to 
produce particles formed by more compounds, generally an active principle and a 
biocompatible polymer, at the same time with controlled particle size and distribution. This 
is the case of encapsulation and co-precipitation. Furthermore, the principles of the same 
techniques can be applied to purposes different from micronization. In SAE (Supercritical 
Antisolvent Extraction), SC-CO2 is used as antisolvent and the aim is to fractionate different 
materials; in SFEE (Supercritical Fluid Extraction from Emulsions) SC-CO2 is again used as 
antisolvent, but for drying particles already produced in the emulsion step. 
2.3.1 Supercritical Antisolvent Extraction (SAE) 
The Supercritical Antisolvent Extraction (SAE) is a challenging combination of supercritical 
fluid extraction (SFE) technique and supercritical antisolvent micronization (SAS) 
technique. The SAE process is conceptually very similar to SAS, but the scope of the process 
is the recovery of one or more solid compounds from a liquid mixture. It consists of the 
continuous flow of SC-CO2 and of the liquid mixture in a pressurized precipitation vessel. If 
the process conditions have been properly selected, the liquid is rapidly extracted by the 
supercritical fluid and recovered in a separation vessel, while the solid precipitates at the 
bottom of the precipitation vessel, where it is collected. The liquid solution is sprayed in the 
precipitation vessel to produce a very large liquid surface, due to the formation of small 
liquid droplets. In this way, the rate of solubilization of the liquid phase in the supercritical 
medium is strongly enhanced. The process is performed at operating conditions at which 
the liquid solvent is completely soluble in SC-CO2 and the compound to be recovered is not 
soluble in SC-CO2. The knowledge of solubility data on the liquid solvents and of the solids 
in SC-CO2 is important for the proper selection of process temperature and pressure. The 
process performances are controlled by the thermodynamics of the system and by the mass 
transfer mechanism. The advantage of the use of a supercritical fluid is the enhanced mass 
transfer in the separation of the undesired liquid compounds, and the selective 
precipitation of the product of interest. A limitation of this process is the possible formation 
of a ternary mixture liquid/solid/SC-CO2. Indeed, the presence of the liquid can induce an 
increase of the solubility of the solid compounds in SC-CO2. In this case, part of the solid is 
retained in the fluid phase, removed by SC-CO2, and lost in the liquid recovered in the 





Until now, SAE has been used in a limited number of processes, but it has a large potential 
for future applications, especially in the separation of high added value substances, such as 
antioxidants, often combined with oils and fats soluble in SC-CO2. The compound to be 
selectively recovered can be naturally present in the liquid mixture, as in the case of lecithin 
in soybean oil. The phospholipids are insoluble, and the seed oil is soluble in SC-CO2. The 
oil solubilized in SC-CO2 is extracted and recovered in a separator operated at low pressure, 
and lecithin precipitates as a solid powder [263]. In the same way, Andersson et al. [264] 
used SAE to separate digalactosyldiacylglycerol, used in the preparation of liposomes or in 
oil-in-water emulsions, from oat oil. The oil was sprayed in a vessel and SC-CO2 removed 
the other components of the oil except digalactosyldiacylglycerol, which precipitated with a 
purity of 97%. 
In other cases, the compound of interest is solubilized in a liquid solvent as the result of a 
previous process or as pre-treatment. Mukhopadhyay and Singh [265] dissolved crude 
lecithin in hexane, because the oil contained in the raw material is more soluble in hexane 
than the pure lecithin. During the antisolvent extraction the dissolution of CO2 in the 
solution causes a large partial molar volume reduction of hexane and a reduction of its 
solvent power for lecithin. Pure lecithin is then selectively precipitated, and the oil is 
removed with the hexane by the SC-CO2. 
Propolis is usually dissolved in EtOH or EtOH/water mixtures to remove insoluble 
material such as waxes and detritus from the hive, thus obtaining the solution called 
propolis tincture. It contains a high concentration of flavonoids, which are used in a wide 
range of cosmetic and health food preparations for their antimicrobial properties. Catchpole 
et al. [266] developed a combined supercritical antisolvent/extraction process for the 
fractionation of propolis tincture to obtain flavonoids and essential oil fractions by 
extraction, and to remove high molecular mass components by antisolvent precipitation. 
Flavonoids are practically insoluble in pure CO2, but sufficiently soluble in CO2+EtOH to 
enable their separation from high molecular mass and/or more polar components. In the 
first step of the process, supercritical CO2 is used both as anti-solvent to precipitate high 
molecular weight components, and as a solvent to extract the EtOH and soluble 
components of the propolis. This extract is then fractionated in two separation steps to 
create a concentrated flavonoids fraction as the primary product, and an essential oil/EtOH 
fraction as a secondary product. 
An improvement of the SAE process could be its combination with SFE in a two-step 
process developed using the same apparatus. First, the compounds of interest are extracted 





CO2-solvent is delivered to another vessel and, changing the operating conditions, the solid 
is precipitated by the SAS technique. A similar approach was used by Aro et al. [267] in 
performing the fractionation of oat lipids using the semi-industrial plant described in this 
thesis work, and coupling SFE and SAS techniques in separate steps. In the first step, SC-
CO2 is used to extract the undesired triacylglycerols and moisture from the matrix of 
groated oat or oat flakes, and in the second step, SC-CO2 with EtOH as modifier is used to 
extract the polar lipids from the treated matrix. The solution EtOH-polar oat lipids is 
separated in a low pressure vessel and concentrated to 1/50 of the original volume. Finally, 
the antisolvent separation is performed and the polar lipids are precipitated and collected, 
while EtOH is removed by SC-CO2. 
2.3.2 Supercritical Fluid Extraction from Emulsions (SFEE) 
Supercritical Fluid Extraction from Emulsions (SFEE) is a novel process proposed by 
Chattopadhyay et al. [268] to obtain particles of nanometric and micrometric size with very 
narrow particle size distribution. The process consists of producing an oil-in-water, or 
multiple emulsions, in which the organic solvent contains the compound to be micronized. 
The precipitation of the compound takes place in the emulsion droplets, well separated 
from each other by the presence of water. SC-CO2 is then used to extract the organic phase 
form the emulsions, and a water suspension in only one step is obtained, which could be 
directly used in some specific formulations. Water can be subsequently removed by 
conventional drying processes. The inventors suggest the use of high-speed centrifugation 
followed by decantation, by which dried particles with very narrow particle size 
distribution are obtained. In this process, the role of SC-CO2 is to extract the solvent from 
the emulsion without solubilizing the compound itself. 
The size of the particles depends on the size of the emulsion droplets; therefore, depending 
on the efficiency of the emulsification step, nano or microparticles with a very narrow size 
distribution can be obtained. Using this technique, cholesterol acetate, griseofulvin and 
megestrol acetate were micronized in the form of water suspensions with particle diameters 
ranging between 0.1-1 µm, measured in the suspension as processed [269]. Organic solvents 
such as EtAc, toluene or DCM and dispersing agent (surfactants) as PVA, pluronics, 
lecithins, Span 80 or Tween 80 have been used in the emulsion process. After the drying 
step, the particles obtained are prismatic-like and crystalline in morphology. The process 





2.3.3 Co-precipitation, encapsulation, formulation 
A new trend in the use of SCF-based micronization techniques is the design of composite 
particles with several purposes [13,34,36,89,110,271]. These include the preparation of 
sustained-release drugs by incorporating the active compound, mainly pharmaceutical or 
nutraceutical, in a slow-dissolving (bio-degradable or bio-erasable) matrix, the stabilization 
of fragile molecules (mainly bio-molecules) in the solid form, and the bio-availability 
enhancement of poorly soluble compounds by incorporating the active compound in a fast-
dissolving hydrophilic excipient [110]. Different kinds of formulations are developed 
according to the final purpose. Polymer/drug co-formulations and inclusion complexes, 
such as drug/cyclodextrin complexes, can be used either for extended and delayed release 
or to enhance poorly water-soluble compounds’ solubility. 
The main method of obtaining controlled release is to incorporate the biologically active 
agents within biopolymers or bio-compatible polymers, basically in the form of 
microcapsules and microspheres. Microcapsules are microparticles formed by an active 
agent core wrapped by a polymeric shell (core-and-shell system). The release rate of the 
drug is then determined by the drug diffusion through the polymeric core. Microspheres 
are polymer microparticles in which the active agent is uniformly dispersed at molecular 
level or in aggregate form (matrix system). The rate of drug release is determined either by 
the degradation of the polymer (erosion), the diffusion of the drug through the matrix, or 
the swelling of the polymer and the consequent diffusion of the agent solubilizing the drug 
[272-275]. In some cases, other compounds different from biopolymers are used. These 
include mainly lipids or phospholipids [276]. 
Cyclodextrins are bucket-shaped oligosaccharides produced from starch. As a result of their 
molecular structure and shape, they possess a unique ability to act as molecular containers 
by entrapping guest molecules in their internal cavity and altering the physical, chemical, 
and biological properties of guest molecules. Cyclodextrin are hydrophilic on the outside 
surface, leading to a very fast dissolution in aqueous media, but hydrophobic on the inside, 
permitting a stable inclusion of poorly soluble molecules of a suitable size [241,277]. 
Formulation of therapeutic proteins in dry form is often required to improve their stability 
and excipients, such as sugars, are used to improve the stability and to drive the particle 





3 AIMS OF THE STUDY 
 
The general aim of this research was to attest the feasibility of micronization of some 
pharmaceuticals and food ingredients using SCF-based techniques. At the same time a valid 
guidelines for performing SCF micronization of compounds with different natures was 
found. In particular, several objectives were intended. 
• To obtain controlled particle size and morphology of the micronized compounds 
using the SAS technique, and investigate the reproducibility of the process at 
different physical plants, different micronization modes (batch and semi-
continuous) and different scale plants (laboratory and semi-industrial). The 
possible modifications induced to the compounds by the process, in terms of 
polymorphism, pseudo-polymorphism and crystal habit have been monitored. 
• To investigate the process in relation to the precipitation mechanism, and 
formulate and confirm some hypothesis of particle formation with the support 
of visual observation of the precipitation evolution. The study could help in 
tracing a direction for the micronization of other compounds. 
• To explore the use of another SCF-based micronization technique, namely SAA, 
in case of compounds that cannot be processed using SAS, and compare the two 
techniques. 
As a result of the whole study, the knowledge and the background acquired were intended 
to be used for transferring the SCF micronization technology to the food industry that still 





4 MATERIALS AND METHODS 
4.1 Materials 
4.1.1 Compounds 
4.1.1.1 Pharmaceutical compounds (I, III-V) 
Cromolyn sodium purity 98% (mw=512.34) was kindly given by Italchimici (Pomezia, 
Italy). The solubility of cromolyn sodium in water is of about 120 mg/mL at 24°C. The 
chemical structure is shown in Figure 1. It is an antiflammatory drug frequently used in the 
therapy of chronic asthma. As for many other drugs used for aerosol delivery, the problem 
of the control of particle size and distribution is one of the major concerns for an efficient 
delivery to the lung. Details can be found in (III). 
 
Figure 1. Chemical structure of cromolyn sodium 
Nalmefene HCl purity of 99.9% (mw=375.9) was given by Biotie Therapies Corp. (Turku, 
Finland). The solubility profile of nalmefene HCl in liquid solvents was also obtained from 
Biotie Therapies Corp. The approximate solubility in EtOH is 10.9 wt% at room 
temperature. Untreated material had been crystallized from water and the crystals had a 
squared shape with the two main dimensions ranging between 70-90 μm and 90-120 μm 
respectively. The chemical structure is shown in Figure 2. Nalmefene is an opioid 
antagonist [284-286]. Details can be found in (I, IV). 
 





Rifampicin with a purity of 99.9% (mw=822.94) was supplied by Sigma–Aldrich (Italy). The 
approximate solubilities in DMSO, NMP, MeOH, EtAc and EtOH were measured at room 
temperature and were 120, 80, 60, 40 and 7 mg/mL, respectively. It is practically insoluble 
in water. The chemical structure is shown in Figure 3. Rifampicin is an antibiotic mainly 
used for the treatment of tuberculosis, but it is also used in the therapy of meningitis and 
infections of the biliary routes. 
 
Figure 3. Chemical structure of rifampicin 
Salbutamol sulphate (mw=576.7) was given by Orion Pharma (Espoo, Finland). The 
approximate solubilities of salbutamol sulphate were measured at room temperature in 
different solutions and they were 0.5 mg/mL in EtOH, 2.3 mg/mL in EtOH/water 
95:5 v/v, and 5.8 mg/ml in EtOH/water 90:10 v/v, respectively. The chemical structure is 
shown in Figure 4. Salbutamol sulphate is a drug used in the treatment of asthma. 
 
Figure 4. Chemical structure of salbutamol sulphate 
4.1.1.2 Biopolymer (II) 
Polyvinyl alcohol (PVA) with an hydrolization grade of 99.8% (mw=30’000-70’000) was 
supplied by Sigma–Aldrich (Milan, Italy). It is a water-soluble polymer made by hydrolysis 





about 22 wt%. Untreated PVA is a fine powder formed of irregular particles with size 
ranging from about 50 to 250 µm. The chemical structure of the monomer is shown in 
Figure 5. Among biopolymers, PVA is widely recommended for pharmaceutical 
applications as a carrier of active compounds, as in the case of production of capsules or 
spheres for medical purposes. Details can be found in (II). 
 
Figure 5. Chemical structure of PVA 
4.1.1.3 Food ingredient (V) 
Adipic acid purity 99.5% (mw=146.14) was supplied by Sigma-Aldrich (Italy). It is also 
called hexanedioic acid and is a white, crystalline compound of C6 straight-chain 
dicarboxylic acid, which is slightly soluble in water and soluble in EtOH and acetone. The 
chemical structure of adipic acid is shown in Figure 6. Adipic acid is used in plastic 
processing (production of nylon 6.6), as excipient in drugs (tablet lubrificant, constituent of 
tablet coatings) and in food production (as flavouring, leavening, and pH control agents 
with E-number E355). Details can be found in (V). 
 
Figure 6. Chemical structure of adipic acid 
4.1.2 Liquid solvents (I-V, unpublished results) 
The liquid solvents were supplied by Sigma-Aldrich (Milan, Italy). EtOH, DMSO, MeOH 
with purity of 99.9% acetone with purity of 99.8% and EtAc with purity of 99.5% were used 





anhydrous with purity of 99.8% and MeOH with purity of 99.9% were used for the analyses 
(III, IV). The solvents used in the micronization processes are classified by the International 
Conference on Harmonization (ICH) as follows: EtOH, DMSO, EtAc, acetone Class 3 
solvents with residual solvent limit in drug substances fixed at 5000 ppm; and MeOH 
Class 2 solvent with residual solvent limit fixed at 10 ppm [111]. 
4.1.3 Other materials (I-V) 
Carbon dioxide (CO2) purchased from SON (Napoli, Italy) and by AGA (Helsinki, Finland), 
and nitrogen (N2) purchased from SON (Napoli, Italy), were used in the micronization 
processes (I-V). Ammonium thiocyanate (supplied by Sigma-Aldrich, Milan, Italy), NaCl 
purity 99% (supplied by Fluka, Sigma-Aldrich Milan, Italy), and triethylamine p.a. grade 
(supplied by Fluka, Sigma-Aldrich Finland Oy, Helsinki, Finland) were used in the analyses 
(III, IV). Urea purity 99.5%, purchased from Sigma-Aldrich (Italy), was used as habit 
modifier in SAS precipitation of adipic acid (V). 
4.2 Apparatuses 
4.2.1 Micronization by supercritical antisolvent (SAS) technique 
4.2.1.1 SAS laboratory plant (I, II, IV, V) 
The laboratory apparatus used for semicontinuous antisolvent precipitation is located at the 
University of Salerno (Italy) and is represented schematically in Figure 7. In the SAS 
experiments, the liquid solution containing the solute is delivered by an HPLC pump to the 
heated high pressure precipitation vessel (P) through a stainless steel nozzle. SC-CO2 is 
pumped by a diaphragm high-pressure pump, pre-heated to the process temperature and 
delivered through another inlet port located on the top of the precipitation vessel. The 
pressure in the precipitation vessel is regulated by a micrometering valve. The produced 
powder is collected on a stainless steel frit located at the bottom of the vessel. The liquid 
solvent is recovered in a second collection vessel (S) located downstream, at lower pressure, 
regulated by a backpressure valve. Manometers, flow-meters, temperature controllers and 
thermocouples complete the apparatus. A more detailed description of the plant can be 







Figure 7. Schematic representation of SAS laboratory scale apparatus: C) CO2 storage vessel; 
L) liquid solution; P) precipitator; S) liquid separator. 
The windowed SAS apparatus (II) differs from the one described above only as regards the 
precipitator, which consists of a stainless steel cylindrical vessel with two quartz windows 
put along two longitudinal sections (Figure 8). The windows allow visual observation of the 






Figure 8. SAS quartz windowed precipitator 
In GAS experiments (II), a vessel with the same characteristics as the one used for SAS 
experiments was used. The inlet port of CO2 is located at the bottom of the precipitation 
vessel and the outlet is on the top. The GAS windowed plant has the same characteristics as 
the SAS windowed plant. 
4.2.1.2 SAS pilot plant (I) 
The pilot plant is located at MTT Agrifood Research Finland, Jokioinen (Finland) and is 
represented schematically in Figure 9. It is a closed loop plant consisting of a CO2 storage 
vessel (C), an extraction unit (E), a precipitation unit (P), two liquid separators (S1, S2), two 
pumps and a heat exchanger. A stainless steel basket is located inside the precipitator and 
at its bottom a filter allows the collection of the product. Gaseous CO2 is cooled in a shell 
and tube heat exchanger, condensed and recirculated to the storage vessel. The liquid 
solution is delivered to the precipitator by a piston pump. Liquid CO2 is delivered using a 
diaphragm pump. The liquid solution and SC-CO2 are fed to the precipitator through a 
tube-in-tube injection system. Similar injection devices have been used for general purpose 
atomization and by several authors for SAS processing [21,177,289]. The liquid solvent is 
recovered in the separators. During a precipitation test the pressure in the precipitator is 
regulated by a micrometering valve located upstream the separator. A more detailed 






Figure 9. Schematic representation of SAS semi-industrial scale apparatus: C) CO2 storage 
vessel; L) liquid solution; E) extraction vessel; P) precipitation vessel; S1, S2) liquid separators 
4.2.1.3 SAS process description 
An SAS experiment begins by delivering CO2 to the precipitation vessel until the desired 
pressure is reached and a steady antisolvent flow is established. Pure liquid solvent is then 
sent through the nozzle to the vessel at the operating flow rate. This procedure is aimed at 
obtaining steady-state composition conditions during the solute precipitation. Then the 
liquid solution is delivered through the nozzle at the same flow rate. The experiment ends 
when the delivery of the liquid solution to the vessel is interrupted. However, supercritical 
CO2 continues to flow for a certain time to wash out from the vessel the residual content of 
solvent solubilized in the supercritical antisolvent. When the washing process is completed, 
the CO2 flow is stopped, and the vessel is depressurized down to atmospheric pressure. 
The GAS procedure is different from the SAS experiments: the liquid solution is placed 
inside the vessel that is then filled with supercritical CO2 up to the desired pressure. The 
first part of the process is operated in batch mode allowing CO2 to pressurize and diffuse 





with a constant CO2 flow rate. A more detailed description of the procedure of SAS 
experiments can be found in (I, II, IV, V). 
4.2.2 Micronization by supercritical assisted atomization (SAA) technique (III) 
4.2.2.1 SAA laboratory plant 
The SAA apparatus is represented schematically in Figure 10 and consists of two high-
pressure pumps that deliver the liquid solution and CO2 to a heated bath and then to the 
saturator. The saturator, or mixer, (M) is a high-pressure vessel loaded with stainless steel 
perforated saddles. The solution produced in the saturator is sprayed through a thin-wall 
80 µm diameter injection nozzle into the precipitator (P). N2 is taken from a cylinder (N), 
heated in an electric heat exchanger (H) and sent to the precipitator to assist evaporation of 
the liquid droplets. The precipitator is an electrically heated stainless steel vessel operating 
at atmospheric pressure. A stainless steel frit located at the bottom of the precipitator allows 
the powder collection. A condenser (S) located after the precipitator is used to recover the 
liquid solvent. Manometers, temperature controllers and thermocouples complete the 
apparatus. Further details are described in (III) and some information about the plant can 
also found elsewhere [230,247,252,290]. 
 
Figure 10. Schematic representation of the SAA apparatus: C) CO2 cylinder; L) liquid solution; 





4.2.2.2 SAA process description 
The SAA process is based on the use of a packed saturator characterized by a large contact 
surface between liquid solution and CO2 and a long residence time. Thus, the dissolution of 
the gaseous stream in the liquid solution is promoted up to near-saturation conditions. In 
the saturator, SC-CO2 dissolves in the liquid solution (formed by an organic solvent or 
water and a solid solute) before the atomization in a thin wall injector, and forms the 
ternary solution. 
SAA takes advantage of two mechanisms of atomization, namely pneumatic atomization 
and decompressive atomization illustrated in Figure 11. Pneumatic atomization takes place 
when a high-speed fluid flow pushes the solution into the injector. Droplet dimensions 
depend on the saturator pressure, injector diameter and geometry as well as some 
parameters, such as flow rates, viscosities and surface tensions of the two fluids. This is also 
the principle of the generic gas atomization process [289]. Decompressive atomization is 
caused by the mixing between CO2 and the solvent, and the efficiency of the atomization is 
due to the fast release of CO2. The rapid depressurization, occurring while passing from the 
high-pressure saturator into the low-pressure precipitator, leads the CO2 moving from the 
liquid solution in which was dissolved into the gaseous state. The fast expansion from 
inside to outside of droplets enhances their fragmentation. The secondary droplets are then 
rapidly dried by warm N2 causing the micrometric and submicrometric particle 
precipitation. 
 
Figure 11. (a) pneumatic atomization; (b) decompressive atomization 





4.3 Analytical methods 
4.3.1 Powder morphology 
4.3.1.1 Scanning Electron Microscopy (I-V) 
Samples of the powder precipitated in all the experiments were observed by a Scanning 
Electron Microscope (SEM). Several SEM images from different parts of the precipitation 
vessel were taken for each run to verify the powder uniformity. Details can be found in (I-
V). 
4.3.2 Particle size distribution 
4.3.2.1 Image analysing (I-V) 
Particle size and distribution of all the compounds were evaluated from SEM images using 
the Sigma Scan Pro Software. Histograms representing the particle size distributions were 
best fitted using Microcal Origin Software. Details can be found in (I-V). 
4.3.2.2 Laser scattering diffraction (III) 
Particle size analysis of cromolyn sodium was also performed by a laser diffractometer 
using the laser scattering (LS) technique. The smallest particle diameter detectable with the 
instrument is 0.05 µm. Measurements on each sample were repeated at 2 min intervals for 
20 min. Details and the procedure can be found in (III). 
4.3.3 Drug purity and degradation 
4.3.3.1 Liquid chromatography (III, IV) 
Purity and degradation of nalmefene HCl was evaluated by HPLC (high performance 
liquid chromatography) analysis (IV). Duplicate analyses were performed on each batch of 
SAS processed nalmefene HCl. Degradation of cromolyn sodium was evaluated by HPLC-
UV/vis analysis of the untreated material and SAA processed powder (III), using a method 
according to Radulovic et al. [291,292]. Details and methods can be found in (III, IV). 
4.3.3.2 Headspace gas chromatography (IV) 
EtOH residue in untreated and micronized nalmefene HCl was measured by a headspace 
(HS) sampler coupled to a gas chromatograph (GC) equipped with a flame ionization 
detector. GC conditions were as described in the USP [293] with some minor modifications 
(IV). Analyses were performed on each batch of processed drug in triplicate. Details and 





4.3.4 Drug crystallinity and structure 
4.3.4.1 X-ray analysis (I, III-V) 
The X-ray diffractograms of the powder samples were recorded using a diffractometer 
operating at 40 kV and 20 mA with Ni-filtered CuKα radiation operating at room 
temperature. Samples were placed in the holder and flattened with a glass slide to ensure a 
good surface texture. The measuring conditions varied depending on the compound 
analysed. Details and methods can be found in (I, III-V). 
4.3.4.2 Differential scanning calorimetry (I-V) 
Thermograms of processed compounds were recorded on a differential scanning 
calorimeter (DSC) using Mettler STARe system. The temperature axis and cell constant of 
DSC were previously calibrated with indium standard materials. Powder sample was 
accurately weighed into an aluminum pan and an empty aluminum pan was used as a 
reference. Different analytical conditions were used depending on the compound. Details 
and methods can be found in (I-V). 
4.3.4.3 Thermogravimetric analysis (IV, V) 
The presence of solvates or hydrates in the powders was determined by thermogravimetric 
analysis (TGA). The solvent/water loss was determined by placing the sample in alumina 
crucibles and heating it with a temperature program different for each compound. The 
thermobalance was coupled to a mass spectrometer (V). Details and methods can be found 
in (IV, V). 
4.3.4.4 Fourier transform infrared spectroscopy (V) 
The spectra of adipic acid were obtained by using a FT-IR (Fourier transform infrared) 
spectrometer at a resolution of 0.5 cm-1. Scan signals were averaged to reduce the noise. The 
samples were ground and mixed thoroughly with potassium bromide (KBr) as an IR 
transparent matrix, and prepared in form of compressed discs. Details and method can be 





5 RESULTS AND DISCUSSION 
The research work presented here has been carried out using SCF-based micronization 
techniques, where mainly SC-CO2 has been used as antisolvent or alternatively as co-solute. 
The SAS process has been reproduced with different plants and at different scales, and the 
process has been scaled-up from the laboratory scale to the semi-industrial scale. The 
application to pharmaceutical or related compounds and a food ingredient as well as the 
use of different solvents are presented. In addition, the possible modifications of the 
micronized compounds have been studied in terms of particle size and distribution, 
polymorphism, crystallinity and amorphousness. 
5.1 Control of particle size and spherical morphology in SAS process (I, II) 
A successful micronization by SAS requires that the compound to be micronized is not 
soluble in SC-CO2 and that the solvent used to solubilize the solid compound has a good 
affinity with SC-CO2. For nalmefene HCl it was possible to verify in a previous study that it 
is not soluble in SC-CO2 using a variable-volume view-cell [294]. Moreover, the 
precipitation of crystals from the system already at 45°C and 100 bar was observed, which 
provided also the information that for the given ternary system, antisolvent precipitation 
takes place in the liquid phase. When this kind of study cannot be performed, it is necessary 
to perform some micronization experiments in order to scan the different operating 
conditions corresponding to different phases in the thermodynamic equilibrium of the 
system. The VLEs of the binary system solvent-antisolvent are a good starting point for 
identifying the phase equilibrium at which the precipitation takes place and the 
corresponding operating conditions [295,296]. The more common VLE behaviour of two 
components in a mixture is represented by a type I system, according to the classification of 
Van Konynenburg and Scott. It is usually reported on isothermal pressure-molar fraction 
diagrams (P-x, as in Figure 12 and Figure 14) in which a closed loop envelops the two-phase 
region. The maximum of the two-phase equilibrium curve is the mixture critical point 
(MCP). 
In the micronization of nalmefene HCl (I) it was supposed that nano-particles were 
obtained in the supercritical region well above the MCP of the mixture solvent-antisolvent. 
Indeed, the irregular spherical shape of the particles suggests a generation by a gas-to-
particles mechanism in absence of liquid surface tension. The coalescence of the particles 
supported this hypothesis, and it may be related to the particle-to-particle interactions 
developed in the colloidal suspension during the precipitation (I, II). The behaviour of 





other compounds by Reverchon et al. [101]. In the case of PVA (II) the windowed 
precipitator allowed to observe the precipitation of this kind of particles from a “fully 
developed” supercritical phase. The colour of the fluid phase was transparent when only 
solvent and antisolvent were present and changed to orange when precipitation started. 
The colour transition is related to the sudden change of the refractive index that is 
characteristic of the passage through a critical point. Moreover, the intensity of the colour 
depends on how close the conditions are to the MCP. The same phenomenon can be 
observed also for pure CO2 [297]. The same behaviour was observed for the binary system 
DMSO-CO2 when some experiments with a variable volume cell were performed [298]. The 
jet at the exit of the injector was very short (1-2 mm) and sometimes not visible at all. 
Submicro- and microparticles of nalmefene HCl and PVA were produced when the SAS 
operating point was near the corresponding MCP at given temperature, and their spherical 
regular shape suggests that they were formed from droplets produced by the atomization 
of the liquid jet and characterized by their surface tension. The particles were dried during 
the precipitation by the supercritical medium (I, II). Using the windowed vessel, the 
hypothesis of precipitation from near-critical or sub-critical conditions developed for 
nalmefene HCl (I) was confirmed for PVA (II). The powder precipitated from a 
homogeneous transparent gas phase, and the fluid became dark during the precipitation. A 
liquid jet was visible near the injector and the large quantity of particles drifting in the 
system was responsible of the obscuration of the fluid phase. 
A different kind of precipitation takes place when the operating point is positioned in the 
two-phase region of the VLE diagram. At these conditions, there are two phases in 
equilibrium: a liquid phase and a gas phase. The solute is partitioned between the two 
phases in relation to its affinity with them. From the gas phase, spherical submicro- and 
microparticles with the same characteristics as those produced near the MCP are formed. 
From the liquid phase either crystals can be formed, like for nalmefene HCl (I) or a cake of 
material, like for PVA (II). The windowed vessel allowed to see the distinct meniscus 
between the liquid phase on the bottom and the gas phase above it. Moreover, by varying 
SC-CO2 flow rate it was also possible to see how the volumetric ratio between the two 
phases changed. The precipitation of the solute was observed from both phases. 
For the formation of a “droplet confined” liquid expanded solution [102], balloons of 
nalmefene HCl and PVA of several tenths of microns in size were generated at sub-critical 
conditions far from the MCP. The liquid surface tension keeps the droplet shape that 
expands until super-saturation is reached on the surface, where the precipitation starts (I, 





Droplets are therefore first expanded and then dried [16]. Using the windowed vessel it was 
noted that during the precipitation the fluid is grey also in this case, as was observed in the 
case of formation of microparticles, but the colour is darker. The obscuration of the fluid 
may be due to the formation of larger particles. 
5.2 Understanding of the modification of the VLE by the solute in SAS 
process (I, II, IV, V) 
Predicting particle formation on the basis of binary VLE diagrams is not conclusive, because 
when the third component is added to the system, it contributes to the VLE with different 
influences depending on the structure of the solute itself and the kind of solvent used. The 
choice of solvent is also related to this observation, and the use of DMSO in many works 
(see literature review chapter) is not causal; indeed, it has a good affinity with SC-CO2 and 
does not have a strong interaction with a relevant number of solid compounds. However, 
also in this case the solute may modify the VLE diagram [103]. 
The influence of PVA on the system DMSO-CO2 was investigated by visual observation 
through the windowed precipitation vessel (II). In particular, in the experiment performed 
at 120 bar 60°C, XCO2=0.98 precipitation from one homogeneous subcritical phase was 
observed, although the operating point falls in the two-phase region of the VLE diagram of 
the binary system (Figure 12). The adding of the solid compound enlarges the two-phase 
region, because the affinity solvent-antisolvent is decreased. Increasing the percentage of 
PVA in the system, this behaviour is intensified and it is evident that the MCP of the system 
moves to higher pressures (II). In Figure 12, which reports data previously calculated [298], 
the continuous line represents the interpolation of experimental data for DMSO-CO2 VLEs 
at 60°C. The discontinuous lines represent the hypothesized equilibrium lines formed when 
the third, solid component, PVA is added to the system. The symbols are the operating 
points at different process conditions and, depending on the concentration, the operating 
points have to be considered with respect to the correspondent curve. In particular it is 
interesting to note that at 140 bar, 60°C, XCO2=0.99 (▲) the point changes its position 
compared to the MCP and moves away from it at the increase of concentration. In the same 
way at 120 bar, 60°C, XCO2=0.99 (x) decreasing the concentration, the point is nearer to the 







Figure 12. Interpolation of experimental data for DMSO-CO2 VLEs at 60°C (continuous line) 
[298] and curves at different concentrations of PVA in DMSO (discontinuous lines) at the 
same temperature. The symbols indicate operating points of some experiments performed in 
(II) and the molar fraction can be read on the abscissa. 
EtOH is not often used in the SAS technique because of its strong interaction with the 
solute; indeed, during the micronization of nalmefene HCl (I, IV) two main observations are 
evinced. First, the VLE of the system EtOH-CO2 is modified by the solute and the 
equilibrium curve corresponding to 60°C moves towards the curve corresponding to higher 
temperatures (I). Second, the solvent modifies nalmefene HCl form from hydrate to 
anhydrous (IV). 
The influence of adipic acid on the system acetone-CO2 is different and cannot be explained 
with the simplified VLEs used in the other cases (V). Large crystals are obtained at 40°C and 
different pressures, corresponding also to operating points far from the two-phase region 
where supercritical or subcritical conditions were expected (Figure 14). A possible 
explanation of this fact is that due to the partial solubility of adipic acid in the mixture SC-
CO2 – acetone, adipic acid is partly solubilized in the fluid phase until supersaturation 
occurs. This kind of high pressure ternary system can be defined as an expanded liquid 
[109,299,300]. In this hypothesis, adipic acid precipitates from a ternary solution solvent-
antisolvent-solute, and a liquid-like nucleation and growth process is obtained. The process 
is mainly controlled by the residence time of the solute in the precipitator and is different 





The same behaviour is noted using EtOH as solvent (unpublished data). At the same 
operating conditions at which nalmefene HCl precipitated as spherical microparticles, that 
is 150 bar and 40°C (I), adipic acid precipitated in the form of needle-like crystals several 
millimetres long (Figure 13). The same results were obtained at different pressures, as in the 
SAS precipitation form acetone. 
 
Figure 13. SEM image of adipic acid precipitated by SAS from EtOH at 40°C, 150 bar. 
The binary systems EtOH-CO2 and acetone-CO2 are different, but in both cases, at the 
operative conditions used in the experiments, the system should be in supercritical 
conditions well above the MCP (Figure 14). The adipic acid influences the systems in the 
same way, and a high pressure expanded liquid region is formed in both cases (V). 
 
Figure 14. Original representation of experimental data from Day et al. [301] for EtOH-CO2 and 





5.3 Role of the injector in the succesful particle production by SAS 
process (I, II) 
In the SAS process, the injector has a key in successful micronization because it increases 
the contact surface between the liquid solution and the antisolvent, thus improving the 
mass transfer. 
In the case of PVA, if the micronization was performed at supercritical conditions, the 
shape and the size of the injector had no influence on the final size of the particles because 
no droplets were formed (II). If the micronization was performed in the region near the 
MCP, the size of the injector influenced the particle size and distribution as a consequence 
of the droplets formed and dried. When the injector had not the proper diameter size, there 
was no jet break-up and filaments were formed (II). In Figure 15 the different kinds of 
observed jets are reported. To obtain jet break-up using a larger injector, CO2 flow rate has 
to be increased. This is sometimes difficult with a laboratory scale plant, but can be easily 
performed when operating on a larger scale. In the pilot plant used for nalmefene HCl 
micronization, a tube-in-tube injector is used which is 10 times larger than the one on the 
laboratory plant, and a CO2 flow rate of more than one order of magnitude higher than in 
the laboratory scale plant is used. Nalmefene HCl micronized particles have been 
successfully obtained, which have a larger particle size and distribution when compared to 
the one obtained using the laboratory plant, mainly because of the different efficiency of the 
tube-in-tube device (I). 
 
Figure 15. Jet-break up at different conditions: (a) droplets of liquid solution in absence of 
atomization; (b) short spray only just visible at supercritical conditions; (c) long spray visible 
at subcritical conditions. 
If no injector is used in the antisolvent process, the atomization step is not performed, as in 





generated, because the particles are obtained by supersaturation of the expanded liquid (II). 
It can be described as the formation of a disperse phase rich in polymer in an expanded 
liquid continuous phase. In this case the particles are spherical like in the SAS semi-
continuous precipitation, since the disperse phase is organized in droplets. The formation of 
particles with a narrow particle size distribution is related to the absence of the typical 
droplet size distribution obtained in a spray and to the stability of the growth environment 
during the expansion. 
5.4 Control of degree of crystallinity in SAS process (I, II, IV, V) 
The particles produced by the SAS micronization technique presented different degrees of 
crystallinity depending on the operating conditions, the micronized compound and the 
solvent used. PVA, which is a polymer, did not modify its structure and maintained the 
semicrystalline form in all the obtained particles: nanoparticles, submicro- and 
microparticles and balloons (II). 
Nalmefene HCl, on the other hand, showed a high crystallization rate in EtOH. At 
subcritical conditions and conditions near the MCP, particles with different degrees of 
crystallinity were formed (from amorphous to 70% crystallinity), depending on the process 
temperature (I) or the CO2 molar fraction (IV). These two factors influence the 
crystallization rate of nalmefene HCl in EtOH. High temperatures and high CO2 molar 
fractions seem to favour the kinetics. In supercritical conditions, amorphous particles of 
nalmefene HCl were formed, because the precipitation was so fast that the particles could 
not organize in regular crystalline structure. The formation of amorphous particles is 
typical for SAS micronization [9]. 
Adipic acid processed using acetone (V) and EtOH as liquid solvents was always obtained 
as crystalline needle-like particles, independently of the solvent or the operating conditions. 
This fact might be related to the precipitation performed in the same phase conditions, 
because of the influence on the system already discussed in the previous paragraph. 
5.5 Polymorphic, pseudo-polymorphic and crystal habit modifications in 
SAS process (IV, V) 
SAS micronization also affected the crystalline structure of nalmefene HCl particles and 
pseudo-polymorphic modifications have been observed. The system CO2-EtOH showed to 
have the property to modify the monohydrate form of nalmefene HCl to anhydrous form 
during the SAS process (IV). A possible explanation is that the water molecules linked to 





the antisolvent process, and were removed perhaps because EtOH can solubilize a small 
amount of water. The solvent-antisolvent ratio, that is the relative amount of CO2 and EtOH 
in the system, affects the role played by the solvent during the micronization. By decreasing 
the quantity of CO2, the influence of the solvent on the final compound form increases. At 
low XCO2, a solvate form can be obtained, which has a different pseudo-polymorphic form 
(IV). 
Similar results were obtained in the case of rifampicin, micronized using several liquid 
solvents and varying the operating conditions (Table 6). At different operating conditions, 
and using EtOH as liquid solvent, rifampicin with different crystal habits was obtained 
[302]. 
Table 6. Operating conditions used for micronization of rifampicin by SAS [302] 








Flow rate sol 
(mL/min) 
Flow rate CO2 
(kg/h) 
0.63 60 130 0.98 505.62 1.5 1.78 
0.63 60 125 0.98 473.13 1.5 1.78 
0.63 60 150 0.98 602.51 1.5 1.78 
EtOH 
0.63 40 150 0.98 780.06 1.5 1.78 
EtAc 2.22 40 150 0.98 780.06 1.5 1.78 
MeOH 2.53 60 150 0.98 602.51 1.5 1.78 
The effect of the operating pressure on rifampicin crystalline structure has been studied at 
60°C and the experiments have been performed at 125, 130, 150 bar. Pressure affected the 
crystal habit of the product; in particular spherical particles have been obtained at 130 bar 
(Figure 16b), and at 150 bar, two different crystal habits coexisting in the same precipitate 
powder were produced (Figure 16c). The DSC and the XRPD analyses showed no 
differences in the traces of the micronized powders obtained at the conditions reported. 





   
   
Figure 16. SEM images of rifampicin precipitated from EtOH at 60°C, 20 mg/mL and (a) 
125 bar, (b) 130 bar, (c) 150 bar; (d) 40°C, 20 mg/mL and 150 bar. 
The effect of the operating temperature on rifampicin crystalline structure has been studied 
at 150 bar by performing the experiments at 40°C and 60°C. By decreasing the temperature, 
different crystals than those previously discussed have been obtained (Figure 16d). They are 
very thin lamellar crystals joined together in a rose-like shape. DSC thermograms showed 
one additional peak at 140°C for the micronized powder compared to the untreated, and it 
can be hypothesized that at 40°C hydrated rifampicin has been produced. XRPD analyses, 
reported in Figure 17, showed that the particles precipitated by EtOH as solvent had a 






Figure 17. DSC thermograms (left) and XRPD diffractograms (right) of rifampicin untreated 
and powders precipitated from EtOH at 150 bar and different operative temperatures. 
Different solvents proved to play different roles in the micronization of rifampicin by SAS. 
Indeed, a monohydrate form was obtained by using EtOH, a dihydrate form was obtained 
by using MeOH and an anhydrous form was obtained by using EtAc. The differences can 
be noted in the DSC and XRPD results reported in Figure 18. Different operating conditions 
have been chosen to work in the same region of the VLE diagram, which is different for 
different solvent-antisolvent systems. 
 
Figure 18. DSC thermograms (left) and XRPD diffractograms of rifampicin precipitated by SAS 
from different solvents. 
The effect of using EtOH as solvent is opposite to the one observed for nalmefene HCl (IV). 
In the SAS micronization of rifampicin, it favoured the formation of a monohydrate, while 
in the case of nalmefene HCl, the formation of the anhydrous was obtained. This clearly 





micronization are related to the specific solvent-antisolvent-solute system and may vary 
with the different compounds to micronize. 
The effect of the SAS process on adipic acid crystals was to modify their shape and to 
produce more regular structures (V). Untreated adipic acid was composed of boulder-like 
crystals with irregular shapes and a large size distribution. With SAS micronization, using 
acetone (V) and EtOH (unpublished data, Figure 13) as solvents, regular needle-like shaped 
crystals were obtained. The addition of urea as crystallization modifier to the system 
modified the crystal habit and the polymorphism of the precipitated adipic acid. Urea 
inhibited the growth of the needles. Prism-like crystals, with the smallest size obtained at an 
optimal urea concentration of 12.5 wt%, or spherical particles, with the surface composed of 
very small crystals, were formed. The choice of urea as crystal modifier was due to its 
capability to form hydrogen bonding with carboxylic groups of adipic acid, thus inhibiting 
the growth of the crystals along the direction of such groups. In Figure 19 the morphology, 
faces and orientation of adipic acid crystals are schematized following the indications in 
literature [303]. The C face is made of carboxylic groups and is the one that grows in the 
needles formation. Urea, attaching to these groups, facilitates the growth of the faces A and 
B, usually slower compared to face C, with the formation of prismatic crystals. The crystal 
size is reduced from a length ranging between 100 and 750 μm to 2.5-30 μm with a mode of 
7.5 μm. The width is approximately one order of magnitude smaller than the length (V). 
 
Figure 19. The morphology, faces and orientation of the molecules with respect to the faces of 
adipic acid crystals, original interpretation from Michaelis [303]. The linear six-carbon chains 
are perpendicular to the C face so that the face is made up entirely of carboxylic groups. 
In the case of spherical particle formation, urea acts as growth inhibitor of adipic acid 
during the “droplet confined” crystallization, producing particles with the surface formed 
by small prismatic crystals of less than 1 µm in length. Upon crystallization, urea is partially 





solid mixture with adipic acid. The urea is not incorporated into the crystal structure, but 
adipic acid is probably transformed to a new crystal polymorph (V). 
5.6 Scale-up of the SAS process from the laboratory to the semi-industrial 
scale (I, unpublished results) 
Scale-up can be considered successful if a compound micronized with the laboratory scale 
plant can be micronized with the pilot scale plant with complete reproducibility of the 
results. Moreover, the productivity has to be high and increased when compared to the 
smaller plant.  
The scale-up of the SAS process has been performed in a semi-industrial plant mainly used 
for SCF extraction processes. Hence, it has been necessary to modify it for the SCF 
micronization process. The plant was already constructed with a view to this possibility. 
Consequently, few changes have been done. There is also the added advantage that the 
versatility of the plant was increased. The two vessels used for the extraction were modified 
by isolating one of them from the rest of the plant and adding the tube-in-tube injection 
device to the other one. A pump for liquid delivery was added to deliver the liquid solution 
in the line terminating with the inlet of the tube-in-tube injector. CO2 was delivered to the 
outer part of the tube-in-tube injector using the existing line. The outlet of CO2 was also 
changed: it was previously on the top of the vessel (Figure 20a), but this configuration 
generated hard to control fluidodynamics, with the formation of vortexes and stagnation 
points inside the vessel. Therefore, the outlet was placed on the bottom of the vessel, below 






Figure 20. Precipitation vessel of the semi-industrial SAS apparatus before (a) and after (b) the 
modifications. Representation of the flow. 
From a design point of view, the most relevant differences between the laboratory and the 
semi-industrial plant are the precipitation vessel volume, which is about 20 times bigger, 
the L/D ratio, which is about 1.3 times larger, and the injector device, which has a final 
injection section that is 3.75 times larger in the semi-industrial plant. A related difficulty 
was the big difference between laboratory and semi-industrial apparatuses in terms of size; 
indeed, the process had to be scaled-up 10 times. This might lead to problems in 
maintaining uniform temperature in the precipitation vessel and constant pressure during 
the process. An electronic valve was used to control the pressure in the vessel and CO2 flow 
rate in relation to the delivery pump, assuring a precise and accurate control. The 
precipitation vessel was heated by a mineral oil jacket, which guarantees uniform 
temperature during the precipitation. 
The scale-up of the SAS micronization process was performed by choosing the operating 
conditions that have given the best results on the laboratory scale plant. For the scale-up, 
the feed ratio solution/antisolvent (R) was the constant parameter, and the CO2 flow rate 
was increased by about 12 times according to the capacity of the semi-industrial plant 
compared to the laboratory plant and the increased section of the injector (I). As a 





All the above-mentioned differences between the laboratory scale and the semi-industrial 
scale had an influence on one of the important parts of the SAS process: the washing step, 
that is, the flowing of CO2 in the vessel after the micronization to remove the residual 
solvent from the vessel. The time required for this step is related to the volume of the 
precipitation vessel and to the CO2 flow rate and on the large scale has to be recalculated. 
The precipitation vessel was considered as a continuous stirred tank reactor (CSTR) [288] 
and the washing time (1) was calculated as 98% of the total time to completely eliminate the 
solvent from the vessel. 










The washing time was calculated per each experiment, because it depends on the CO2 flow 
rate. The scale-up was successful (I) and at the end of the experiments the powder was 
distributed in the precipitation section: 
• on the walls of the inner vessel 
• on the bottom 
• blocked in filter bottom meshes and slits. 
When the quantity of nalmefene HCl processed was increased, it was noted that the same 
amount of material was always lost. Increasing the production could then make the 
percentage of loss negligible. 
After the successful reproduction of nalmefene HCl powder at semi-industrial scale, it was 
interesting to reproduce also data found in literature. Salbutamol sulphate was micronized 
by Reverchon et al. [192] by SAS on laboratory scale using several solvents. The test 
performed at 145 bar, 50°C and 1 mg/mL (salbutamol sulphate in solution of EtOH/water 
90:10 v/v) has been reproduced with the semi-industrial plant and the same shape of 
crystals has been obtained (Figure 21). 
It was proved that the parameters used to scale-up the process in the case of nalmefene HCl 






Figure 21. SEM image of salbutamol sulphate precipitated from EtOH by SAS at 145 bar, 50°C, 
1 mg/mL using the semi-industrial plant. 
5.7 Micronization by SAA as complement to SAS (III) 
The choice in this thesis to work also with the SAA technique, which may be considered as 
complementary to SAS, was linked to the need to have a more complete understanding of 
SCF-based micronization techniques. These two techniques have been already used to 
micronize the same compound, the pigment disperse red 60 [304]. It has been shown that 
with SAS nanometric particles were produced with a low yield, while near-micrometric 
crystalline particles were produced with SAA with higher yield. From a general point of 
view, the results were considered complementary. 
Cromolyn sodium belongs to the category of compounds that cannot be successfully 
micronized using SCF antisolvent techniques, because it is slightly soluble in organic 
solvents, but freely soluble in water (see chapter on materials and methods). Cromolyn 
sodium was micronized with the SAS technique in other works, using a mixture 
water/MeOH (6%wt) and the obtained particles, with a size of 0.1-20 μm, required post 
processing in the oven for 20 hr to eliminate the residual solvent [156,305]. In the present 
work, using the SAA technique (IV), amorphous spherical particles were obtained, and it 
was possible to control the particle size and distribution in the range used for aerosol 
delivery systems without any post processing of the final product. The use of water 
guarantees a real solvent-free process, which can be applied to pharmaceutical compounds 
but also to food ingredients that also have strict regulations about the use of solvents in 
their processing [7,112-114]. 
The precipitation temperature is a parameter to be carefully controlled during the process. 
Indeed, too low temperatures do not guarantee the drying of the particles and too high 





140°C (III). The temperature chosen depends on the solvent used and on the compound to 
be micronized. Varying the concentration of the compound in water is possible to control 
particle size and distribution: with an increase in concentration, particle size increases and 
particle size distribution enlarges. Cromolyn sodium particles obtained by SAA were 
amorphous at all the operative conditions tested, differently from the SAS technique, in 
which it was possible to control the degree of crystallinity by varying the operating 
conditions (see paragraph on crystallinity). The reason for this is that the precipitation by 
SAA is so fast that the material has no time enough to rearrange on both the nanometric 
and the micrometric scale. This fact tends to stabilize the amorphous character of the 
powders. The amorphous structure of the powders was stable in closed vials at room 
temperature for at least 12 months, which is the time period that has been monitored until 
now. 
The SAA process, similarly to SAS, had an effect on the solid state of cromolyn sodium, in 
particular on the amount of water molecules entrapped in the structure. Cromolyn sodium 
has the peculiar attitude to form non-stochiometric hydrates and to absorb and liberate 
water in a continuous manner. A variable number of molecules of water (as many as nine) 
can be accommodated in the crystalline structure, depending on the relative humidity 
[306,307]. Water molecules can accommodate in different ways: part in the interstitial space 
that can be readily lost, and part combined with sodium ions that are more difficult to be 
removed [308]. While untreated cromolyn sodium contains water in both positions in the 
structure, the micronized powders contains water only in the interstitial positions. 
Because the process is based on the formation of a spray of the solution and a subsequent 
explosion of the droplets for the decompressive action of CO2, the droplet size distribution 
is responsible of the final particle size. Consequently, it is easier to obtain submicrometric 
and micrometric particles than nanoparticles. The production of nanoparticles would be 
possible if some aspects of the process are further improved. For example, it could be 
possible to vary the operating pressure in the mixer to improve the secondary atomization 
and to study the high pressure VLEs that are formed for the system solvent-cosolute-solute. 
The knowledge of both techniques is important, because the borderline between the 
antisolvent, co-solvent and co-solute role of SC-CO2 in the micronization process is 
sometimes very smooth and completely dependent on the system considered. The 
antisolvent effect has to be avoided in SAA, otherwise the compound could precipitate in 
the mixer, and the co-solvent effect has to be avoided in SAS, as otherwise the compound 






The supercritical antisolvent technique is proved to be an effective micronization technique 
for pharmaceuticals, food ingredients and related compounds. The rich literature collected 
shows that the interest in this field is in continuous development, and there is a tendency to 
apply the technique to more specific fields, for example encapsulation of pharmaceuticals 
and nutraceuticals or “ready to use” formulations. However, supercritical fluid processing 
is at present mainly an experimental field, and the real-life process applications are most 
often only variations from those studied in detail in previous research projects. 
In this study, the compounds processed with SAS have been also used as model 
compounds for the determination of some general considerations regarding the 
micronization process. The visual observation clearly showed that the morphology and the 
size of the particles are directly dependent on the high pressure VLEs generated in the 
system. This finding can be considered generally valid for several systems and can be used 
to predict the results and to plan preliminary micronization tests. The prediction cannot be 
complete and definitive, mainly because the interaction between solvent-antisolvent, which 
can be thermodynamically measured by variable-volume view-cell, is affected by the 
compound to be micronized. However, with some preliminary specific experiments and 
some considerations on these, it is possible to guide the process towards the desired target. 
The possibility to obtain the desired results by adding an additive, for example to control 
the growth during particle formation, improves the versatility and enlarges the application 
field of the process. 
The SAS process showed a tendency to influence not only the particle size, particle size 
distribution and morphology of the product, but also the crystallinity, the crystal habit and 
the pseudo-polymorphism. In particular, solvents such as EtOH, MeOH and EtAc may 
have a role in controlling the solvation or desolvation processes that may take place during 
the micronization. One of the most important results of this study is that the SAS process 
can be performed using physically different plants and that this technology can be 
transferred from the bench scale to the industrial scale, obtaining the reproducibility of the 
results, with a large production and an high process yield. 
The co-solute SCF-based micronization techniques, in particular SAA, seem to be a very 
good complement to the antisolvent techniques. Water-soluble compounds and compounds 
that cannot be processed by SAS, can be successfully micronized by SAA. In this study, 
amorphous particles of a compound that was difficult to micronize by SAS technique 





relevant change was observed in the polymorphism. The technique is very promising and it 
is worth it to explore other solvents than water, also as co-solvent combinations, as well as 
different operating conditions, to investigate the potentiality of this technique and develop 
a model. 
With this research work some concepts about SCF micronization have been settled and 
some fundamental knowledge, together with general interpretations, have been presented. 
Further investigations are needed in the future to find the still missing complete model and 
the process equations that may convert these experimental techniques into unit operations 
used in the industrial field. The general rules found for the antisolvent micronization 
techniques can be transferred to other SCF-based techniques that use the same principle. In 
particular, in the food field the antisolvent technique may be used to fractionate solid 
compounds by performing a selective precipitation, combining also that process with the 
already industrially used extraction processes. 
The knowledge of both antisolvent and co-solvent techniques allows to process a more 
wide variety of compounds, pharmaceuticals, food ingredients, bio-polymers and others, 
both hydrophilic and hydrophobic. Moreover, the principles on which these 
complementary techniques are based can be compared and developed to find more 
practical applications in the industrial field in the future. The food industry can take 
advantage of the SCF antisolvent and cosolvent micronization mechanisms for the 
development of products with special functionality. Starting from the first step of the 
production (which might be the extraction of the material of interest), through the 
manufacturing steps (which may include purification or fractionation), until the final 
product (which might be encapsulated or suspended in a drink or in some specific 
formulation), the principles widely discussed in this thesis can be used. The added 
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